 
CLINICAL RESEARCH IN INFECTIOUS DISEASES 
 
 
STATISTICAL ANALYSIS PLAN  
for 
DMID Protocol : 14-0112  
Study Title : 
A Phase II, Double-Blind, Multicenter, 
Randomized, Placebo -Controlled Trial to Assess 
the Safety, Reactogenicity and Immunogenicity of 
Two Doses o f Multimeric -001 (M -001) Followed 
by Seasonal Quadrivalent Influenza Vaccine  
 
NCT  03058692  
 
Version 1.0  
 
DATE: 09 September 2019 
THIS COMMUNICATION IS PRIVILEGED AND CONFIDENTIAL  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- ii - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  STUDY TITLE  
Protocol Number Code:  DMID Protocol: 14-0112 
Development Phase:  Phase II 
Products:  1. M-001 manufactured by BiondVax  
2. Licensed seasonal quadrivalent inactivated influenza vaccine (IIV4)  
3. Normal saline placebo  
Form/Route:  Intramuscular (all products) 
Indication Studied:  Influenza 
Sponsor:  Division of Microbiology and Infectious Diseases  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Clinical Trial Initiation Date:  9 April 2018 
Clinical Trial Completion Date:  Expected April 2020 
Date of the Analysis Plan:  09 Septem ber 2019 
Version Number:  1.0 
This study was performed in compliance with Good Clinical Practice . 
Information contained in this publication is the property of Division of Microbiology and Infectious Diseases and is confidential. This 
information may not be disclosed to third parties without written authorization from Division of Microbiology and Infectious Diseases.  This 
report may not be reproduced, stored in a retrieval system or transmitted in any form or by  any means - electronic, mechanical, recording  or 
otherwise - without the prior authorization from Division of Microbiology and Infectious Diseases.  This document must be returned to Division 
of Microbiology and Infectious Diseases upon request.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- iii - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  TABLE OF CONTENTS  
Study Title   ..................................................................................................................................... ii 
Table of Contents ........................................................................................................................... iii 
List of Abbreviations ..................................................................................................................... vi  
1. PREFACE  .....................................................................................................................1  
2. INTRODUCTION  ........................................................................................................2  
2.1. PURPOSE OF THE ANALYSES  ................................................................................2  
3. STUDY OBJECTIVES AND ENDPOINTS  ................................................................3  
3.1. STUDY OBJECTIVES  ................................................................................................3  
3.1.1.  PRIMARY OBJECTIVES ............................................................................................3  
3.1.2.  SECONDARY OBJECTIVES  .....................................................................................3  
3.1.3.  EXPLORATORY OBJECTIVES  ................................................................................3  
3.2. OUTCOME MEASURES  ............................................................................................4  
3.2.1.  3.2.1 PRIMARY OUTCOM E MEASURES  ................................................................4  
3.2.2.  SECONDARY OUTCOME MEASURES  ...................................................................4  
3.2.3.  EXPLORATORY OUTCOME MEASURES  ..............................................................4  
3.3. STUDY DEFINITIONS  AND DERIVED VARIABL ES ...........................................5  
4. INVESTIGATIONAL PLAN  .......................................................................................6  
4.1. OVERALL STUDY DESIGN AND PLAN  .................................................................6  
4.2. DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUPS  ...................................................................................................6  
4.3. SELECTION OF STUDY POPULATION  ..................................................................6  
4.4. TREATMENTS  ............................................................................................................6  
4.4.1.  TREATMENTS ADMINISTERED  .............................................................................6  
4.4.2.  IDENTITY OF INVESTIGATIONAL PRODUCT(S)  ................................................6  
4.4.3.  METHOD OF ASSIGNING SUBJECTS TO STUDY AR MS 
(RANDOMIZATION)  ..................................................................................................7  
4.4.4.  SELECTION OF DOSES I N THE STUDY  ................................................................7  
4.4.5.  SELECTION AND TIMING OF DOSE FOR EACH SUBJECT  ...............................7  
4.4.6.  BLINDING  ...................................................................................................................7  
4.4.7.  PRIOR AND CONCOMITANT THERAPY  ...............................................................7  
4.4.8.  TREATMENT COMPLIANCE  ...................................................................................8  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
Table of Contents  (continued) 
- iv - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  4.5. IMMUNOGENICITY AND S AFETY VARIABLES  .................................................8  
4.5.1.  SAFETY VARIABLES  ................................................................................................8  
4.5.2.  IMMUNOGENICITY VARIA BLES  ...........................................................................8  
5. SAMPLE SIZE CONSIDERATIONS  .......................................................................10  
6. GENERAL STATISTICAL CONSIDERATIONS  ....................................................11  
6.1. GENERAL PRINCIPLES  ..........................................................................................11  
6.2. TIMING OF ANALYSES  ..........................................................................................11  
6.3. ANALYSIS POPULATIONS  ....................................................................................11  
6.3.1.  MODIFIED INTENT -TO-TREAT (MITT) POPULATION  .....................................11  
6.3.2.  PER PROTOCOL POPULAT ION .............................................................................11  
6.3.3.  SAFETY ANALYSIS POPULATION  ......................................................................12  
6.4. COVARIATES AND SUBGROUPS  .........................................................................12  
6.5. MISSING DATA  ........................................................................................................12  
6.6. INTERIM ANALYSES AND DATA MONITORING  .............................................12  
6.7. MULTICENTER STUDIES  .......................................................................................13  
6.8. MULTIPLE COMPARISONS /MULTIPLICITY  ......................................................13  
7. STUDY SUBJECTS  ...................................................................................................14  
7.1. DISPOSITION OF SUBJE CTS .................................................................................14  
7.2. PROTOCOL DEVIATIONS  ......................................................................................14  
8. IMMUNOGENICITY EVALUATION  .....................................................................15  
8.1. PRIMARY IMMUNOGENICI TY ANALYSIS  ........................................................15  
8.2. SECONDARY IMMUNOGENICITY ANALYSES  .................................................15  
8.3. EXPLORATORY IMMUNOGE NICITY ANALYSES  ............................................16  
9. SAFETY EVALUATION ..........................................................................................17  
9.1. DEMOGRAPHIC AND OTHE R BASELINE CHARACTERISTICS  .....................17  
9.1.1.  PRIOR AND CONCURRENT  MEDICAL CONDITIONS  ......................................17  
9.2. MEASUREMENTS OF TREA TMENT COMPLIANCE  .........................................17  
9.3. ADVERSE EVENTS ..................................................................................................17  
9.3.1.  SOLICITED EVENTS AND SYMPTOMS  ...............................................................17  
9.3.2.  UNSOLICITED ADVERSE EVENTS  ......................................................................18  
9.4. DEATHS, SERIOUS ADVERSE EVENTS AND OTHER  SIGNIFICANT 
ADVERSE EVENTS ..................................................................................................19  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
Table of Contents  (continued) 
- v - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  9.5. PREGNANCIES  .........................................................................................................19  
9.6. CLINICAL LABORATORY EVALUATIONS  ........................................................19  
9.7. VITAL SIGNS AND PHYS ICAL EVALUATIONS  ................................................19  
9.8. CONCOMITANT MEDICATIONS  ..........................................................................20  
10. REPORTING CONVENTIONS  ................................................................................21  
11. TECHNICAL DETAILS  ............................................................................................22  
12. SUMMARY OF CHANGES IN THE CONDUCT OF THE STUDY OR 
PLANNED ANALYSES  ............................................................................................23  
13. REFERENCES  ...........................................................................................................24  
APPENDICES  ...............................................................................................................................25  
Appendix 1.  Table Mock -Ups .....................................................................................................26  
Appendix 2.  Figure Mock -Ups....................................................................................................94  
Appendix 3.  Listings Mock -Ups ...............................................................................................113  
Appendix 4.  NCA TEMPLATE  ................................................................................................135  
  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- vi - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  LIST OF ABBREVIATIONS 
AE Adverse Event/Adverse Experience 
AESIs  Adverse Events of Special Interest  
ALT  Alanine Aminotransferase  
AST  Aspartate Aminotransferase 
BP Blood Pressure  
BUN  Blood Urea Nitrogen 
C Celsius  
CFR Code of Federal Regulations 
CI Confidence Interval 
CRF  Case Report Form  
CSR Clinical Study Report 
DMID  Division of Microbiology and Infectious Diseases 
DSMB  Data and Safety Monitoring Board 
EDC  Electronic  Data Capture  
ELISA  Enzyme-linked Immunosorbent Assay 
ER Emergency Room  
F Fahrenheit  
GBS  Guillain -Barre Syndrome 
GGT  Gamma Glutamyl Transferase  
GMT  Geometric Mean Titer  
GMP  Geometric Mean Percentage 
GMFR  Geometric Mean Fold Rise  
HAI/HI  Hemagglutin in Inhibition 
ICH International Conference on Harmonisation 
IIV Inactivated influenza vaccine 
IIV4  Quadrivalent inactivated influenza vaccine  
IRB Institutional Review Board  
ITT Intention to Treat  
L Liter  
LLN  Lower Limit of Normal  
M-001 Multimeric -001 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
List of Abbreviat ions (continued) 
- vii - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  mcg Microgram  
MedDRA  Medical Dictionary for Regulatory Activities   
mEq  Milliequivalent  
mg Milligram 
mITT  Modified Intent- to-Treat  
mL Milliliter  
MAR  Missing at Random 
MCAR  Missing Completely at Random  
MN Micro Neutralization  (refers to neutraliz ation antibodies)  
MNAR  Missing Not at Random 
N Number (typically refers to subjects)  
Neut  Neutralization (refers to neutralization antibodies)  
NIH National Institutes of Health  
PBS Phosphate Buffered Saline 
PI Principal Investigator  
PK Pharmacokinetics  
PP Per Protocol  
PT Preferred Term  
RBC Red Blood Cell 
RCD  Reverse Cumulative Distribution  
SAE  Serious Adverse Event  
SCR Seroconversion Rate 
SD Standard Deviation 
SDCC  Statistical and Data Coordinating Center  
SMC  Safety Monitoring Committee  
SOC  System Organ Class 
SOP Standard Operating Procedures  
U Units  
ULN Upper Limit of Normal 
WBC White Blood Cell 
WHO World Health Organization 
 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 1 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  1. PREFACE  
This Statistical Analysis Plan (SAP) for DMID Protocol 14-0112, ‚ÄúA Phase II, Double- Blind, Multicen ter, 
Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two 
Doses of Multimeric -001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine‚Äù, describes and 
expands upon the statistical information presented in the protocol. 
This document describes all planned analyses and provides reasons and justifications for these analyses. It 
also includes sample tables, figures , and listings  (TFLs)  planned for the final analyses. Regarding the final 
analyses and Clinical  Study Report (CSR), this SAP follows the International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (I CH) Guidelines, as indicated 
in Topic E3 (Structure and Content of Clinical Study Reports), and more generally is consistent with Topic E8 
(General Considerations for Clinical Trials) and Topic E9 (Statistical Principles for Clinical Trials). The 
structure  and content of the SAP provide sufficient detail to meet the requirements identified by the F DA and 
ICH, while all work planned and reported for this SAP will follow internationally accepted guidelines published by the American Statistical Association and  the Royal Statistical Society for statistical practice.  
This document contains four sections : (1) a review of the study design, (2) general statistical considerations, 
(3) comprehensive statistical analysis methods for safety  and immunogenicity outcomes, and ( 4) a list of 
proposed tables, figures , and listings. Within the table , figure , and listing mock -ups (Appendices 1, 2, and 3, 
respectively), references to CSR sections are included. Any deviation from this SAP will be described and 
justified in amendments to this SAP and/or in the CSR, as appropriate. The reader of this SAP is encouraged 
to also review the study protocol for details on conduct of the study and the operational aspects of clinical 
assessments. 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 2 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  2. INTRODUCTION 
Seasonal influenza occurs annually, and in the United States it causes an estimated 100 to 600 thousand 
hospitalization s annually and up to 50,000 deaths a year [ 1,2,3]. The continued emergence of novel influenza 
A vir uses in humans‚Äîincluding subtypes H5N1, H3N2v, H7N7, H9N2, 2009 H1N1, and most recently 
H7N9, underscores the need for focused efforts to prepare for the next influenza pandemic [ 4-9]. Current 
licensed inactivated influenza vaccines (IIVs) are good  for preventing influenza but are less effective than 
desired . One approach to improve the effectiveness of IIVs is to prime the immune system with epitope- based 
vaccines. The M -001 vaccine from BiondVax consists of  
that are  The 
epitopes in the vaccine are common to a large majority of influenza virus strains, and the epitopes are recognized by both the humoral and cellular arms of the immune system [10]. 
The goal of this clinical trial is to assess in healthy adults the safety, reactogenicity, and immunogenicity of two doses of multimeric -001 (M-001) vaccine followed by the 2018-2019 seasonal quadrivalent IIV (IIV4). 
2.1. Purpose of the A nalyses 
These analyses will assess the safety, reactogenicity,  and immunogenicity of two doses of M-001, 
manufactured by BiondVax, or saline placebo, followed by a single dose of seasonal IIV4  for up to 200 days 
after the first study vaccination . They will be presented  in the CSR, with a subset for compilation in a 
‚Äútopline‚Äù report  for expedited delivery (exhibits indicated by asterisks in the appendices). 

Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 3 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  3. STUDY OBJECTIVES  AND ENDPOINTS  
3.1. Study  Objectives  
3.1.1. Prim ary Objectives  
Safety  
‚Ä¢ To assess the safety as measured by vaccine related adverse events, reactogenicity, and laboratory 
adverse events of two doses of M-001 vaccine, each dose administered approximately 21 days apart  
Immunogenicity  
‚Ä¢ To assess the T cell r esponses to M-001 component peptides following two doses of M-001 
3.1.2. Secondary Objectives  
Safety  
‚Ä¢ To assess all serious adverse events (SAEs) following receipt of each dose of M -001 vaccine or 
placebo, each dose separated by approximately 21 days, through the end of the study 
‚Ä¢ To assess all unsolicited non-serious AEs following receipt of each dose of M-001 or placebo, each dose separated by approximately 21 days, through 21 days after each dose of M-001 or placebo  
Immunogenicity  
‚Ä¢ To assess the se rum HAI and Neut antibody responses to the 2018-2019 IIV4 vaccine viruses 
3.1.3. Exploratory Objectives 
Immunogenicity  
‚Ä¢ To assess the IgG responses to the M-001 vaccine after receipt of placebo or two doses of M-001 vaccine and following receipt of licensed IIV4  
‚Ä¢ To assess the T cell responses to M-001 component peptides following one dose of M-001 or placebo  
‚Ä¢ To assess T cell responses to M-001 component peptides following receipt of licensed IIV4 
‚Ä¢ To assess the T cell cross -reactive responses to current seasonal in fluenza virus antigens and 
pandemic influenza virus antigens following e ach vaccination (M -001 and IIV4)  
‚Ä¢ To assess the longevity of T cell responses to M -001 peptides, seasonal influenza virus antigens 
and pandemic influenza virus antigens 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 4 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  3.2. Outcome Measure s 
3.2.1. 3.2.1 Primary Outcome Measures 
Safety  
‚Ä¢ Occurrence of vaccine -related SA Es from the time of the first study vaccination (M -001 or 
placebo) through approximately 6 months after the second M-001 study vaccination  
‚Ä¢ Occurrence of solicited injection site and systemic reactogenicity events on the day of each study 
vaccination throu gh approximately 7 days after each M -001 vaccination  
‚Ä¢ Occurrence of clinical safety laboratory adverse events from the time of each study vaccination of M-001 through approximately 7 da ys after each M -001 vaccination 
Immunogenicity  
‚Ä¢ Geometric Mean Percentage of T cell subsets expressing perforin, CD107a, IFN-Œ≥, TNF-Œ±, and IL2, alone or in combination, in CD4 and CD8 cells after stimulation with M-001 component peptides at baseline (Day 1) and 14 days after the second dose of M-001  
3.2.2. Secondary Outcome Measures  
Safety  
‚Ä¢ Occurrence of all SAEs, from the time of receiving the first M -001 or placebo study vaccination 
through the end of the study  
‚Ä¢ Occurrence of all unsolicited non-serious AEs from the time of first study vaccination through 21 days after each M -001 vaccination  
Immunogenicity  
‚Ä¢ For HAI and Neuts, the percentage of subjects achieving seroconversion ( defined as either a pre-
vaccination titer <10 and a post-vaccination titer ‚â•40 or a pre-vaccination titer ‚â•10 and a minimum four-fold rise in post- vaccination antibody titer)  to IIV4 vaccine viruses from Day 172 to Day 200 
‚Ä¢ For HAI and Neuts, the percentage of subjects with an antibody titer of 40 or greater and geometric mean titers ( GMTs ) vs. IIV4 vaccine viruses on Days 1, 43, 172 and 200 
3.2.3. Exploratory Outcome Measures  
Immunogenicity  
‚Ä¢ Percentage of subjects achieving seroconversion (defined as a minimum four-fold rise in post-vaccination ELISA antibody titer) and GMTs of ELISA antibody vs. M-001 from Day 1 to Days 22, 43, 78, 172 and 200  
‚Ä¢ Geometric Mean Percentage of T cell subsets expressing perforin, CD107a, IFN-Œ≥, TNF-Œ±, and 
IL2, alone or in combination in CD4 and CD8 cells after stimulation with M -001 peptides at 
baseline (Day 1) and approximately 14 days after one dose of M-001, 56 days following the 
second dose of M-001, and immediately prior to and 14 and 28 days after IIV4 
‚Ä¢ Percentage of T cell subsets expressing perforin, CD107a, IFN-Œ≥, TNF-Œ±, and IL2, alone or in combination, in CD4 and CD8 cells after stimulation with other influenza A antigens (including 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 5 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  seasonal and pandemic influenza antigens) at baseline (Day 1), approximately 14 days after each 
study vaccination, 56 days following the second study vaccination and immediately prior to and approximately 28 days after IIV4 
‚Ä¢ Percentage of influenza- specific T cell memory subsets expressing discrete memory markers 
(CCR7, CD4 5RO, and CD57) at baseline (Day 1), approximately 56 days after the second dose of 
placebo or M-001 and immediately prior to and approximately 28 days after the IIV4 dose  
3.3. Study Definitions and Derived Variables   
Geometric mean percentages (GMPs)  are calcu lated as the product of the observed percentages raised to the 
1/Nth root, where N is the number of observed values.  
The baseline value for cellular  and humoral immunity will be  defined as the value obtained on Day 1 prior to 
M-001 vaccination. 
M-001 anti body response after baseline will be summarized by GMTs and the proportion of subjects 
achieving seroconversion (defined as a minimum four-fold rise in post-vaccination ELISA ant ibody titer) at 
each time point, with corresponding 95% confidence intervals. 
For individual subjects, fold rise will be calculated as the ratio of: ùëùùëùùëùùëùùëùùëùùëùùëù‚àíùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ ùëùùëùùë£ùë£ùëùùëùùë£ùë£ ùëùùëùùë£ùë£ùëùùëùùë°ùë°ùë°ùë°
ùëùùëùùë°ùë°ùë°ùë°‚àíùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£ùë£
ùë£ùë£ùë£ùë£ùëùùëùùë£ùë£ùëùùëùùë£ùë£ ùëùùëùùë£ùë£ùëùùëùùë°ùë°ùë°ùë°, where pre-vaccination 
value is always the result obtained at Day 1, prior to the first M -001 dose. 
Seroconversion for HAI and Neut assays  is defined as either a pre- vacci nation titer <  1:10 and a post-
vaccination titer ‚â• 1:40, or a pre -vaccination titer ‚â•  1:10 and a minimum four-fold rise in post-vaccination 
titer. 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 6 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  4. INVESTIGATIONAL PLAN  
4.1. Overall Study Design and Plan  
DMID 14 -0112 is a Phase II randomized, double-blind, placebo- controlled trial in a sample of 120 males and 
non-pregnant females, 18 to 49 years old, inclusive, who are in good health and meet all eligibility criteria.  
This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of two  priming doses of 
M-001 followed by administration of IIV4.   
Subjects are assigned randomly to 1 of 2 study arm s (60 subjects per study arm ) to receive two doses of the 
M-001 vaccine or placebo followed by a single dose of IIV4 (see Table 1).  
‚Ä¢ Group A re ceives two 1 mg doses of M-001, on Days 1 and 22 followed by a single dose of IIV4 
on approximately Day 172 (¬± 30).   
‚Ä¢ Group B receives saline placebo on both Days 1 and 22, followed by a single dose of IIV4 
approximately on Day 172 (¬±30). 
4.2. Discussion of Study Design, Including the Choice of Control Groups  
This study uses a placebo  concurrent control design. Saline was chosen to act as an inactive placebo control as 
a comparator for  the safety, reactogenicity , and immunogenicity of two doses of M-001 vaccine a s well as for 
the downstream immunogenic effects post-seasonal IIV4 vaccination. 
4.3. Selection of Study Population  
The study population for this clinical trial is 120 males and non- pregnant females, 18-49 years of age, 
inclusive, who meet all eligibility criteria. Eligibility criteria ensure that subject s are in good health  at the time 
of vaccination and have not recei ved (and do not plan to receive) therapies  that would interfere with immune 
response to the study products, such as non-study vaccines or immunos uppressive therapies. Exact eligibility 
criteria can be found in the protocol sections 5.1 and 5.2. S ubjects ar e recruited from the general population at 
the participating Vaccine Trial and Evaluation Unit (VTEU) sites that have substantial experience cond ucting 
large influenza vaccine studies.  
4.4. Treatments 
4.4.1. Treatments Administered  
Two doses of either multimeric M -001 vaccine or saline placebo are administered per subject‚Äôs randomized 
assignment , followed by administration of seasonal IIV4 vaccine to all subj ects. 
4.4.2. Identity of Investigational Product(s) 
Seasonal Quadrivalent Inactivated Influenza Vaccine (IIV4)  
IIV4 f or intramuscular injection is indicated for active immunization against influenza disease caused by 
influenza virus subtypes A and type B present in the vaccine.  The 2018-2019 Fluzone Quadrivalent IIV4  used 
in the study was formulated  by Sanofi  to contain HA of each of the following four influenza strains  
recommended for the 2018-2019 Northern Hemisphere influenza season: A/Michigan/45/2015 X-275 
(H1N1 ), A/Singapore/INFIMH-16- 0019/2016 IVR -186 ( H3N2 ), B/Maryland/15/2016 BX-69A (a 
B/Colorado/06/2017- like vir us, B Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 7 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  M-001  
Multimeric -001 (M-001) vaccine developed by BiondVax is
 
 
Placebo  
Sterile normal saline will be used as the placebo .  
4.4.3. Method of Assigning Subjects to Study Arm s (Randomization)  
Enrollment/randomization is  done through the enrollment module in the electronic data capture system, 
maintained by the SDCC.  
Eligible subjects are randomized and assigned in a [1:1 ] ratio to re ceive two priming doses 21 days apart of 
either M -001 (Group A) or saline placebo (Group B), followed by seasonal IIV4 vaccination (all groups). 
Randomization is stratified  by prior receipt of the 2017-2018 influenza vaccine and by site. The 
randomization is based on a variable blocked scheme to provide an approximately balanced allocation to the 
study arm s during the study. 
4.4.4. Selection of Doses in the Study  
Multiple  studies of M -001 have assessed the safety and immunogenicity profile in healthy adults, and t heir 
results suggested that immune responses were improved with increasing  doses up to 1 mg, with no saf ety 
concerns identified.  The 1 mg dosage was selected for this trial based on the elevated HAI antibody responses 
in that study group in the placebo -controlled BVX -006 trial [[STUDY_ID_REMOVED]], where no SAEs or safety 
concerns were observed.  
4.4.5. Selection and Timin g of Dose for Each Subject  
All subjects receive the assigned vaccination at Day 1 and Day 22 (+2 days), followed by a single dose of IIV4 on approximate ly Day 172 ( ¬±30 days). 
4.4.6. Blinding  
This trial is double -blinded; subjects, investigators, study personnel performing any study- related assessments 
following study vaccine administration, and laboratory personnel performing antibody assays are blinded to the treatment assignment.  
The randomization scheme was generated by the SDCC and provided to unblinded study personnel (i.e., pharmacists performing study vaccination preparations and unblinded study vaccine administrators) at the participating VTEU sites who are not involved in study- related assessments or have subject contact for data 
collection following study vaccine administration. 
The Data and Safety Monitoring Board (DSMB) receives data in aggregate and presented by group and may 
request treatment assignment be unblinded for an individual subject if required for safety assessment. The DSMB review s grouped and unblinded data in the closed session only. 
4.4.7. Prior and Concomitant Therapy  
Concomitant medications include any  medications, therapies, or vaccinations  taken in the 60 days prior to 
Day 1 through approximately 21 days after the last M -001/placebo dose received. Medications reported in the 
electronic case report form (eCRF) are limited to those taken within 30 days prior to the first study 

Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 8 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  vaccination through approximately 21 days after the second M-001/placebo dose. In addition, receipt of any 
non-study vaccines is solicited at each clinic visit or phone call  and reported in the eCRF for the entire 
duration of the study.  
Use of new medication should prompt evaluation for the presence of a new diagnosis of chronic medical 
disease or condition. Medications that might interfere with the evaluation of the investigational product were 
not to be used unless absolutely necessary. Medications in this category include the prohibited medications 
per the Subject Exclusion Criteri a. In addition, the site PI or appropriate staff  may identify other mediations 
that should not be used due to a risk to subject safety or assessment of reactogenicity and immunogenicity. 
4.4.8. Trea tment Compliance  
All subjects receive two doses of either M- 001 or saline placebo followed by seasonal IIV4 administered in 
the clinic.   
4.5. Immunogenicity and Safety Variables  
See Table 2 for the schedule of study procedures in DMID protocol 14-0112. 
4.5.1. Safety V ariables  
Safety will be assessed by the frequency and severity of:  
1. All SAEs occur ring from the time of the first study vaccination through the end of the study 
2. Solicited AEs ‚Äì reactogenicity events occurring on the day of each study vaccination through 7 days 
after each M -001 study vaccination: 
a) Injection site  reactions including pruritus, ecchymosis, erythema, induration/swelling, pain, 
and tenderness.  
b) Systemic reactions including fever, feverishness, fatigue, malaise, myalgia, arthralgia, 
headache, and nausea.  
3. Unsolicited AEs ‚Äì non- serious AEs occurring from the time of the first M -001 study vaccination 
through approximately 21 days after the second M-001 study vaccination. 
4. Safety laboratory abnormalities occurring from the time of the first study vac cination through 8 days 
after the last dose of M -001. 
a) Clinical safety laboratory parameters measured: WBC, hemoglobin, platelets, ALT, total bilirubin, and creatinine 
4.5.2. Immunogenicity Variables  
Cellular immunogenicity data will be reported by the Baylor Coll ege of Medicine. These data will include the 
frequency  of influenza- specific T cells as measured by fluorescence- based flow cytometric assay s. The lab at 
Baylor  will also report the percentage of influenza- specific T cells expressing discrete memory marker s 
(CCR7, CD45RO, and CD57), the percentage of CD4 and CD8 T cells expressing perforin, CD107a, IFN-Œ≥, 
TNF -Œ±, and IL2, alone or in combination, the percentage of CD4+ T cell subsets expressing IL-4 or IL -17, T 
follicular helper (TFH) cells (CD4+, CXCR5+ , PD-1+, IL-21+) , T follicular regulatory (Tfr) cells ( CXCR5+, 
PD-1+, CD25+, CD127+ ) , and T regulatory cells (Tregs) (CD25+, Foxp3+) as measured by flow cytometry.   
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 9 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Individual HAI and Neut antibody results will be reported for the IIV4 vaccine strain by the central 
immunology laboratory at St Louis University. Assay results are reported as a reciprocal titer with values of 
10*2k, where k=0, 1, 2, etc. The lower limit of detection for both the HAI and Neut assays is 1:10; values 
below the limit of detection are reported as ‚Äò<10‚Äô, and for analysis are imputed as one- half the limit of 
detection (10/2 = 5). For analysis, the geometric mean of repeated results for each sample will be computed 
and used as the response for all subsequent calculations. The variation arising from multiple measurements for 
an individual at a single time point will not be used in subsequent calculations. See Section  3.3 for definitions 
of derived variables for the analysis of HAI and Neut data.  
Assays to determine serum levels of antibodies to M -001 will be performed by BiondVax. 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 10 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  5. SAMPLE SIZE CONS IDERATIONS  
The study population for this clinical trial was planned to include 120 males and non-pregnant females, 18 to 
49 years old, inclusive, who are in good health and meet all eligibility criteria. The subjects were recruited 
from the general populat ion at the participating VTEU sites that have substantial experience conducting large 
influenza vaccine studies.  
Based on the accrual rate for similar studies, it was expected  that the participating VTEUs would be able to 
enroll this trial in a timely fas hion. Prior experience suggests up to 5% of subjects could be excluded from the 
per protocol analysis for the primary immunogenicity outcome either because they are lost- to-follow-up or 
otherwise do not have data available following the second study vaccination or because they had a protocol 
deviation requiring their exclusion from the per protocol analysis. 
Table 3 indicates the probability of observing one or more safety events, such as solicited injection site or 
systemic reactogenicity events or an unso licited non -serious AE of a particular type, for a single study arm  
(N=60) and all enrolled subjects (N=120).  
Binomial confidence intervals (CI) are widest (have the least precision) when the response rate is 50%. 
Table 4 is presented to indicate the worst-case scenario for precision of observed exact (Clopper- Pearson) 
binomial confide nce intervals.  
With N= 60 subjects per arm and assuming the standard deviation of log GMP is 0.75, the study will have 
80% power to detect a 2.5-fold increase in the GMP of T cell subsets expressing IFN -Œ≥. Table 5 illustrates a 
power analysis considering a range of standard deviations for log GMP and a range of GMP fold- change with 
N=60 subjects per arm, and further includes the power under the conservative assumption of 10% drop out in each study arm . Power is calculated for a two -sided t- test with signific ance level (alpha) 0.05 using PROC 
POWER in SAS 9.4. Utilizing  different  tests instead  of those based on Normal approximations could increase 
the power from what is shown. 
While there will be multiple comparisons performed for this primary immunogenicity objective (for each of 
five parameters alone measured in CD4 and CD8 T cells plus any combinations measured), it is assumed that 
these analyses are not intended to be confirmatory and thus no adjustment for multiple comparisons is considered . Instead, p-value thresholds of p<0.001, p<0.01, and p<0.05 will be considered as strong, 
moderate, and weak evidence of differences between study arms.  These will be indicated in relevant tables 
with ***, **, and *, respectively. 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 11 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  6. GENERAL STATISTICAL CONSIDERATIONS  
6.1. General Principles  
All continuous variables, unless otherwise specified, will be summarized  using the following descriptive 
statistics: n (non -missing sample size), mean, standard  deviation, median, minimum and maximum. Titers will 
be summarized  with geometric means, first across replicates to compute one value for each individual sample 
and then across subjects within a study group. Percentages of cell types will also be summarize d by geometric 
means within each study group. The frequency and percentages (based on the non- missing sample size) of 
observed levels will be reported for all categorical measures. In general, all data will be listed, sorted by 
treatment and subject, and when appropriate by visit number within subject. All summary tables will be 
structured with a column for each vaccination group in the order presented in Table 1 and will be annotated with the total population size relevant to that table/treatment, includin g any missing observations. 
If a substantial number of subjects me et eligibility criteria , but had intercurrent infections that might affect the 
immunoassay results for the vaccine strains, sensitivity analyses will be performed excluding those and qualita tive comparisons will be made with the mITT and PP analyses. 
6.2. Timin g of Analyses 
No interim analysis is planned. 
The final analysis will be performed after the last subject completes the final visit, and the database is cleaned, 
monitored, and locked. A topline report will be generated upon receipt and processing of immunogenicity 
data (T cell responses after stimulation with M -001 peptides and with other Influenza A antigens, and M-001 
ELISA responses) through Day 200. Tables and figures to be included have an asterisk f ollowing the title.  
The CSR will be completed when all primary and secondary endpoint data are available.  All available 
exploratory endpoint data will be included in the CSR, and additional data not available at the time of CSR 
generation wil l be included in one or more addendums, depending on the timing of each set of exploratory 
assays. 
6.3. Analysis Populations  
A tabular listing of all subjects, visits, and observations excluded from the analysis populations will be 
provided in Listing  5. In the  case of mis -randomization, subjects will be analyzed according to the study 
product actually received for all analysis populations.  
6.3.1. Modified Intent -to-Treat (mITT) Population 
The modified intent- to-treat (mITT) population includes all subjects who receive d at least on e dose of study 
vaccine and contributed at least one post-study vaccination venous blood sample for immunogenicity testing 
for which valid results were reported.  
6.3.2. Per Protocol Population  
The per protocol (PP) population includes all subjects i n the mITT su bset with the following exclusions: 
‚Ä¢ Data from all available visits for subjects found to be ineligible at baseline  
‚Ä¢ Data from all visits subsequent to major protocol deviations, such as: 
o Second or third study vaccination not received 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 12 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  o Second or third study vaccination received out of window 
o Receipt of non-study licensed live vaccine within 30 days before or 21 days after each study 
vaccination  
o Receipt of non-study licensed inactivated vaccine within 14 days before or 21 days after each study vacc inatio n 
o Receipt of non-study seasonal influenza vaccine (live or inactivated) within 30 days before or for the duration of the study 
o Receipt of immunosuppressive therapy (e.g., corticosteroids) within 30 days before or after each of the first two study vac cinati ons (Dose 1 and Dose 2) 
‚Ä¢ Data from any visit that occurs out of window 
o Visit 03: Day 14 + 2 days post vaccination 1 
o Visit 04: Day 22 + 2 days post vaccination 1 
o Visit 06: Day 14 + 2 days post vaccination 2 
o Visit 07: Day 21 + 7 days post vaccination 2 
o Visit 08: Day 56 + 7 days post vaccination 2 
o Visit 09: Day 150 ¬± 30 days post vaccination 2 
o Visit 10: Day 14 + 3 days post vaccination 3 
o Visit 11: Day 28 + 7 days post vaccination 3 
6.3.3. Safety Analysis Population 
The Safety Analysis p opulation includes all subjects who received at least one dose of study vaccine. 
6.4. Covariates and Subgroups  
The protocol does not define any formal subgroup analyses, and the study is not adequately powered to 
perform subgroup analyses. 
6.5. Missing Data  
All attempts will be made to colle ct all  data per protocol. As missing data are expected to be minimal, no 
imputation will be performed for missing values. Any data point that appears to be erroneous or inexplicable based on clinical judgement will be investigated as a possible outlier. If  data points are identified as outliers, 
sensitivity analyses will be performed to examine the impact of including or excluding the outliers. Any substantive differences in these analyses will be reported.  
6.6. Interim Analyses and Data Monitoring  
Interim safet y data is reviewed by the DSMB as described in Protocol Section 9.6.2. Interim summary reports 
for the DSMB safety review include enrollment and demographic information, medical history, concomitant medications, physical assessments, clinical laborato ry va lues, solicited reactogenicity events and unsolicited 
AE/SAEs. There were no formal interim analyses planned.  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 13 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  6.7. Multicenter Studies  
Data will be pooled across all three clinical sites.  Center effects are not anticipated because the sites are using 
standardiz ed procedures for vaccination and assessment of solicited and unsolicited adverse events, and the 
study relies on central laboratories for the assessment of immunogenicity endpoints. 
6.8. Multiple Comparisons/Multiplicity  
While there will be multiple compa rison s performed for the primary immunogenicity objective (for each of 
five parameters alone measured in CD4 and CD8 T cells plus any combinations measures), it is assumed that 
these analyses are not intended to be confirmatory and thus no adjustment for m ultiple comparisons is 
considered. 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 14 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  7. STUDY SUBJECTS  
7.1. Disposition  of Subjects  
The disposition of subjects in the study will be tabulated by study arm  (Table 13).  The table shows the total 
number of subjects screened, enrolled, received treatment, received all treatment , completed follow-up, 
completed the final blood draw, and the number completing the study. The composition of analysis 
populations, including reason s for subject exclusion is presented  by study arm  in Table 14. The dates of each 
study vaccination will be summarized by site and study arm in Table 15, and a summary of screening failures 
will be presented in Table 16. 
A flowchart showing the disposition of study subjects, adapted from the Consort Statement [ 11] will be 
included ( Figure  1). This figure will present the number of subjects screened, enrolled, lost to follow-up, and 
analyzed, by study arm . 
A listing of subjects who discontinued dosing or terminated from study follow-up and the reason will be 
included in Listing  2. A listing of all subjects receiving investigational product will be given in Listing  1. 
7.2. Protocol Deviations 
A summary of subj ect-specific protocol deviations will be presented by the reason for the deviation, the 
deviation category, and study arm  for all subjects ( Table 6). Deviations that are considered major deviations 
that will be reviewed for possible subject exclusion from the per protocol population include:  second or third 
study vaccination not received, second or third study vaccination received out of window, receipt of non-
study licensed live vaccine within 30 days before or 21 days after each study vaccination, receipt of non- study 
licensed inactivated vaccine within 14 days before or 21 days after each study vaccination, receipt of non-
study seasonal influenza vaccine (live or inactivated) within 30 days before or for the duration of the study, 
and recei pt of immunosuppressive therapy within 30 days before or after each of the first two study 
vaccinations . All subject-specific protocol deviations and non- subject specific protocol deviations will be 
included in Appendix 3 as data listings ( Listing  3 and Listing  4, respectively).  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 15 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  8. IMMUNOGENICITY EVALUATION 
Analysis of all immune responses will be conducted using the PP population. In addition, for the primary 
endpoint, analysis conducted with the mITT population will be used as a sensitivity analysis. Percentages of 
cell subset responses will be measured by flow cytometry  as described in Section  4.5.2. 
Data listings of HAI and Neut assay results as reported by the central immunogenicity laboratory will be provided in Listing  8, Listing  9, Listing  10, Listing  11, Listing  12, Listing  13, Listing  14, and Listing  15. 
ELISA assay results will be provided in Listing  16, and f low cytometry results will be provided in Listing  17 
and Listing  18. 
8.1. Primary Immunogenicity Analysis 
The primary immunogenicity objective is to determine whether priming with M -001 improves T cell 
responses. The cells are sorted  via flow cytometry, and t he percentages of CD4 + and CD8+ T cells expressing 
perforin, CD107a, IFNŒ≥, TNF -Œ±, IL-2, or any combination of these are calculated as the number of cells 
positive for these proteins divided by the total number of T cells counted in each sample. To compare the T 
cell responses between groups, the following Poisson regression model will be fit for each combination of proteins of interest: 
log(E(Y|X)/Z)=Œ≤
0+ Œ≤ 1*X,  
where Y is the number of cells expressing a given combination of proteins, X is an indic ator variable for 
Group A, and Z (the offset) is the total n umber of T cells in each sample.  Wald tests will be performed to 
evaluate whether there are differences in the expression of T cell subsets between the two study arms.  As 
described in Section  6.8, adjustments for multiple comparisons are not planned. 
GMPs  of CD4 + and CD8+ T cells expressing each combination of proteins and the corresponding 95% 
bootstrap confidence intervals will also be presented  for each study arm Table 22Table 23Table 24Table  25. 
These will be  presented in Table 22 , Table 23, Table 24, and Table 25 and summarized visually in boxplots 
over time in in Figure  2, Figure  3, Figure  4, and Figure  5. 
8.2. Secondary Immunogenicity Analy ses 
Humoral immune responses in terms of strain -specific IIV4 HAI and Neut antibody titers will be summarized 
by study arm at each ti me point. Descriptive summary statistics will be provided for all assays and time points 
including number of subjects with non-missing results, number and percentage of subjects with titers ‚â•1:40, number and proportion of subjects achieving seroconversion, and GMTs along with corresponding 95% CIs. Clopper- Pearson exact confidence intervals will be presented for proportion endpoints. Summaries of humoral 
immunogenicity endpoints are presented in Table 30, Table 31, Table 32, Table 33, Table 34, Table 35, Table 36, and  Table 37. 
HAI and Neut seroconversion by Day 172 or Day 200, the percentage of subjects with titer ‚â•40, and GMT ‚Äôs 
against the 2018-2019 IIV4 vaccine strain on Days 1, 43, 182, and 200 will be summarized as described above. 
The reverse cumulative distributions of HAI and Neut assays against each strain will be displayed in 
Figure  10, Figure  11, Figure 12, Figure  13, Figure  14, Figure  15, Figure  16, and Figure  17. The Spearman 
correlation between HAI, Neut, and M-001 antibody titers will be calculated at each time point over all 
groups. The correlation will be depicted in scatter plots beginning at Figure  18 and  continuing through 
Figure  29. 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 16 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  8.3. Exploratory Immunogenicity Analyses 
ELISA seroconversion and GMTs of the ELISA antibody against M-001 from Day 1 to Days 22, 43, 78, 172, 
and 200 will be presented in Table 44. 
Table 26Table 27Table 28 Table 29  
These percentages will be summarized visually in box plots over time in Figure  6, Figure  7, Figure  8, and 
Figure  9, fo r selected cell subsets .  
GMPs  of influenza- specific CD4+ T cell subsets expressing discrete memory markers (CCR7, CD45RO, and 
CD57) will be summarized at baseline (Day 1) and on study days 15, 36, 43, 78, 172, 186, and 200 
(Table 38) , by study arm . The subject -level percentages  corresponding to selected cell subset s will be 
presented in Figure  30. Analogous summaries will be presented for CD8+ T cells in Table 39and Figure  31. 
The p ercentage of influenza- specific CD4+ cell s ubsets expressing IL- 4 or IL -17, T follicular helper cells 
(CD4+, CXCR5+, PD- 1+, IL -21+), T follicular regulatory (Tfr) cells (CXCR5+, PD-1+, CD25+, CD127+), 
and Tregs (CD25+, Foxp3+) measured by flow cytometry will be summarized at baseline (Day 1) and on 
study days 15, 36, 43, 78, 172, 186, and 200 ( Table 40, Table 41, Table 42, and Table 43, respectively ). 
Boxplots for these percentages will also be presented in Figure  32, Figure  33, Figure  34, and Figure  35.  
 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 17 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  9. SAFETY EVALUATION  
All summaries and analysis of safety data will be presen ted for the Safety Analysis population. Safety 
summaries will be presented overall and by study arm . 
Continuous variables will be summarized using the following descriptive statistics: n (non -missing sample 
size), mean, standard deviation, median, maximum, and minimum. All categorical measures will be 
summarized by the frequency and percentages of observed levels. The denominator for the percentages may 
be based on the number of non- missing observation s for an assessment or based on the number of subjects in 
a population. This will be described for each table. 
9.1. Demographic and Other Baseline Characteristics  
Summaries of age, sex, ethnicity, race, BMI, and prior receipt of seasonal influenza vaccine will be presented 
by site ( Table 17 and Table 18) and by vaccination group ( Table 19 and Table  20). Age will be summarized 
as a continuous as well as categorical variable. Ethnicity is categorized as Hispanic or Latino, not Hispanic, and not Latino, Not Reported, or Unknown. In accordance with NIH reporting policy, subjects may self -
designate as belonging to more than one race or may refuse to identify a race, the latter reflected in the eCRF 
as ‚ÄúNo‚Äù to each racial option. BMI will be summarized as a continuous and a categorical variable, categorized 
as (<30, ‚â•30). S elf-reported history of prior receipt of seasonal influenza vaccine will be categorized by 
influenza season  (2016- 17 only, 2017-18 only, both 2016-17 & 2017-18, neither, or unknown). 
Individual subject listings will be presented for all demographics ( Listing  6). 
9.1.1. Prior and Concurrent Medical  Conditions  
All current illnesses and past pre- existing medical conditions will be coded using the Medical Dictionary for 
regulatory affairs (MedDRA
¬Æ) coded version 22.0 or higher. 
Summaries of subjects‚Äô pre -existing medical conditions will be presented by  MedDRA System organ class 
(SOC) and study arm  (Table 21).  
Individual subject listings will be presented for all medical conditions ( Listing  7). 
9.2. Measurements of Treatment Compliance  
All subjects were to receive three study vaccinations administered in the c linic. The number of study 
vaccinations administered to subjects will be presented by vaccine group as part of the subject disposition table ( Table 13 ).  
9.3. Adverse Events  
An overall summary of all adverse events will be presented in Table 45. A summary of adverse events occurring in 5% or more of subjects in any study arm  will be presented in Table 46. 
9.3.1. Solicited Events and Symptoms  
Solicited injection site and systemic reactogenicity events will be documented from the time of each study 
vaccination (Day 1 (Visit 01) and approximately Day 22 (Visit 04)) through 7 days after each study 
vaccination. They were graded on a scale of 0 (non e), 1 (mild), 2 (moderate), and 3 (severe). Systemic events 
include fever, feverishness, fatigue, malaise, myalgia, arthralgia, headache, and nausea, and the grading scale 
for these can be found in Table 7. The grading scale for fever is included in Table 8. Injection site  events 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 18 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  include pain, tenderness, pruritus, ecchymosis, erythema, and induration/swelling. Ecchymosis, erythema, and 
induration are measured by both functional and measurement grading scales defined in Table 9 and Table 10, 
respectively . 
When calculating the incidence of solicited events, each subject  will be counted once at the highest severity 
following the applic able dose, and any repetitions will be ignored. For summaries presented separately for 
each vaccination, the denominator for pe rcentages will be the number of subjects who received the respective 
vaccination with non- missing data for the event summarized. For summaries over all vaccinations the 
denominator will be the number of subjects who received at least one vaccination with non- missing data for 
the event summarized.  
Additionally, solicited AEs will be analyzed by dichotomizing the response into a binar y variable (none vs 
mild, moderate, or severe) and using 95% CIs calculated using Clopper-Pearson methodology from a 
binomial distribution (SAS Proc Freq with a binomial option) to summarize the proportion of subjects 
reporting each symptom, any injection site symptom, and any systemic symptom ( Table 47). Summaries of 
solicited AEs will be presented separately for each s tudy vaccination as well as overall study vaccinations by 
study arm  (Table 49, Table 50, Table 51, Table 52 , and Table 53). A comparison of the proportion of subjects 
reporting solicited symptoms by study arm will be shown in Table 48, and the proportion of subjects reporting 
solicited symptoms between the first and second study vaccinations will be compared using McNemar‚Äôs test 
in Table 54.  
Listings of systemic and local solicited events will be presented in Listing  19 and Listing  20, respectively.  
Listing  18Listing  19Figur e 36Figur e 37Unsolicited Adverse Events  
Unsolicited , non-serious AEs were documented from the time of the first study vaccination (Day 1 (Visit 01)) 
through approximately 21 days after the second M-001 study vaccination (approximately Day 43 (Visit 07)), and SAEs were collected through the entire study duration (Day 200). All AEs will be MedDRA coded by for 
preferred term  (PT) and SOC. Serious unsolicited adverse events will be reported by detailed listings showing 
the event description, MedDRA PT  and SOC, relevant dates (study vaccinations and AE), severity, 
relatedness, and outcome for each event. Non-serious unsolicited AEs will be summarized as number and percentage of subjects reporting at least one event in each MedDRA PT and SOC, cross tabulated by severity 
and relationship to study product. Additionally, the proportion of subjects and exact 95% CIs (calculated in the same way as above) of AEs in aggregate and by MedDRA categories will be computed.  
Unsolicited a dverse events by subject will be presented in  Listing  21. 
The following summaries f or unsolicited adverse events will be presented by MedDRA system organ clas s, 
preferred term, vaccination and study arm : 
‚Ä¢ Subject incidence and total frequency of adverse events over time by dose with 95% CI (Days 1 -8, 
Days 9 -22) ( Table 55); 
‚Ä¢ Summary of severity and relationship to study product ( Table 56);  
‚Ä¢ Subject incidence and total frequency of related adverse events over time ( Table 57);  
‚Ä¢ Bar chart of AE incidence by severity and MedDRA system organ class and Study Arm  
(Figure  38); 
‚Ä¢ Bar chart of total frequ ency of AEs by relationship to study product and MedDRA system organ 
class and study arm  (Figure 39); 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 19 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  ‚Ä¢ Bar chart of AE incidence by relationship to study product and MedDRA system organ class and 
Study Arm  (Figure  40). 
9.4. Deaths, Serious Adverse Events and other Significant Adverse Events  
Serious Adverse Events were documented from the time of the first study vaccination (Day 1 (Visit 01)) through the end of the study. 
A listing of death and other serious adverse events will be presented by Subject ID, Age (yea rs) Adverse 
Event Description, Adverse Event Onset Da te/End Date, Last Dose Received/Days Post Dose, Reason 
Reported as an SAE, Relationship to Treatment, Alternate Etiology if not Related, Outcome, and Duration of 
Event (days) ( Table 58).  
9.5. Pregnancies  
For any subjects in the Safety population who became preg nant during the study, every attempt will be made 
to follow these subjects to completion of pregnancy to document the outcome, including information 
regarding any complications with pregnancy and/or delivery. Pregnancies and outcomes will be presented in 
Listing  27, Listing  28, Listing  29, Listing  30, and  Listing  31. 
9.6. Clinical Laboratory Evaluations  
Clinical safety laboratory evaluations were performed at baseline and approximately 8 days after Dose 1 and Dose 2 of study vaccination. The grading scale for clinical laboratory evaluations will be presented in 
Table 12. Subject visits with abnormal laboratory results, Grade 1 severity or higher, will be presented in 
Table 59 and Table 60 for Chemistry and Hema tology parameters, respectively.  
The distribution of chemistry results by severity, study day, and vaccination group will be presented in 
Table 61, Table 62, Table 63, and Table 64. Descriptive statistics including mean, standard deviation, median, 
minimu m, and maximum by study day, will be summarized for each parameter in Table 65, Table 66, and 
Table 67. Plots illustrating the change from baseline for each chemistry laboratory par ameter will be 
presented in Figure  41. 
The distribution of hematology results by severity, study day, and vaccination group will be presented in Table 68, Table 69, T able 70, and Table 71. Descriptive statistics including mean, standard deviation, median, 
minimum, and maximum by study day, will be summarized for each parameter in  Table 72, Table 73, and 
Table 74. Plots illustrating the change from baseline for each hematology laboratory parameter will be 
presented in Figure  42. 
A complete listing of individual clinical laboratory results will be presented in Listing  22 and Listing  23. 
9.7. Vital Signs and Physical Evaluations  
Vital sign measurements blood pressure, oral temperature, and pulse . Vital signs were assessed at Day 1, Day  
22, and Day 172, and as needed at the other study visits. The grading system for vital signs can be found in 
Table 11. Vital signs will be tabulated by visit and study arm  (Table 75, Table 76, Table 77, Table 78 , and  
Table 79). A listing of vital findings will be presented in Listing  24. 
Physical examinations may be conducted at any study visit based on indicated symptoms. A listing of 
physical exam findings will be presented in Listing  25. 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 20 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  9.8. Concomitant Medications  
All current medications and medications taken in the 30 days before Study Day 1 (prescription and over-the-
counter drugs) will be recorded in the eCRF, as well as vaccinations, vitamins, and supplements, through 21 
days after the second M -001 study injection. All concomitant medications and vaccinations taken within 60 
days prior to signing the ICF will be recorded on the appropriate data collection f orm prior to the first study 
vaccination. Concomitant medications (vaccines only) will be recorded on the appropriate data collection form after Visit 7 through the end of the study. Assessment of eligibility will also include a review of 
prohibited medica tions (per the exclusion criteria).  
A by -subject listing of the concomitant medication use will be presented  (Listing  26). The use of concomitant 
medications during the study will be summarized by ATC1, ATC2 code and study arm  for the Safety 
population ( Table 80).  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 21 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  10. REPORTING CONVENTIONS 
P-values ‚â•0.001 and ‚â§0.999 will be reported to 3 decimal places; p-values less than 0.001 will be reported as 
‚Äú<0.001‚Äù The mean, standard deviation, and other statistics will be reported to 1 decimal place greater than 
the original data. The minimum and maximum will use the same number of decimal places as the original 
data. Proportions will be presented as 2 decimal places; values  greater than zero but <0.01 will be presented as 
‚Äú<0.01‚Äù. Percentages will be reported to the nearest whole number; values greater than zero but < 1% will be 
presented as ‚Äú<1‚Äù; values greater than 99% but less than 100% will be reported as >99% . Estimated 
parameters, not on the same scale as raw observations (e.g. regression coefficients) will be rep orted to 3 
significant figures.  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 22 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  11. TECHNICAL DETAILS  
SAS version 9.4 or above and R version 3.6 or above will be used to generate all tables, figures and listings.   
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 23 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  12. SUMMARY OF CHANGES I N THE CONDUCT OF THE STUDY OR 
PLANNED ANALYSES  
After the data format for the primary analysis was confirm ed, the planned analysis was changed from what is 
described in the protocol. Instead of utilizing a normal approximation, a Poisson regression model will be fit 
to test for differences between study arms, as described in Section  8.1. 
Additionally, the modi fied Intent -to-Treat population will only be used as a sensitivit y analysis for the 
primary objective. Originally it was also planned for secondary and exploratory objectives involving antibody responses, but these will not be done in the interest of conci seness.  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 24 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  13. REFERENCES  
1. Centers for Disease Control and Prevention. Es timates of death associated with seasonal  
influenza --- United States, 1976-2007. MMWR 2010; 59 (33):1057-62. 
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza- associated 
hospitalizations in the United States. JAMA 2004; 292 (11):1333-40. 
3. Reed C, Chaves SS, Daily KP, Emerson R, Aragon D, Hancock EB, et al. Estimating 
influenza disease burden from population- based surveillance data in the United States. PLoS  
One 2015; 10(2):e0118369. 
4. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus 
isolated from a child with a fatal respiratory illness. Science 1998; 279:393-6. 
5. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999; 
354:916-7. 
6. CDC. Emergence of Avian influenza A/H7N9 Virus Causing Severe Human Illness ‚Äî China, February-April 2013. MMWR 2013 May 10; 62(18):366-71. 
7. Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus H7N7 
associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. 
Proc Natl Acad Sci USA 2004 Feb 3; 101 (5):1356-61. 
8. Perez -Padilla R, de la Rosa- Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory 
failure from swine -origin influenza A (H1N1) in Mexico. N Engl J Med 2009 Aug 13; 
361(7):680-9. 
9. Lindstrom S, Garten R, Balish A, et al. Human infections with novel reassortant influenza A 
(H3N2)v viruses, United States, 2011. Emerg Infect Dis 2012; 187:834-7. 
10. Gottlieb T, Ben -Yedidia T. Epitope-based approaches to a universal influenza vaccine. J 
Autoimmun 2014; 54:15-20. 
11. Drummond, R. CONSORT Revised: Improving the Reporting of Randomized Clinical Tr ials. JAMA . 
2001; 285(15):2006-2007. 
 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 25 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  APPENDICES  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 26 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  APPENDIX 1. TABLE MOCK-UPS  
LIST OF TABLES  
Table 1:  Study Design  ...............................................................................................................31  
Table 2:  Schedule of Study Procedures ....................................................................................32  
Table 3:  Power (%) to Detect Safety Events  ............................................................................33  
Table 4:  Preci sion of Binomial Confidence Intervals ...............................................................34  
Table 5:  Power Analysis for Primary Immunogenicity Endpoint ............................................35  
Table 6:  Distribution of Protocol Deviations by Category, Type, and Study Arm (All 
Enrolled Subjects) .......................................................................................................36  
Table 7:  Subjective Systemic Reactogenicity Grading  .............................................................38  
Table 8:  Quantitative Systemic Reactogenicity Grading  ..........................................................39  
Table 9:  Injection Site Reactogenicity Grading  ........................................................................40  
Table 10:  Injection Site Reactogenicity Measurements  ..............................................................41  
Table 11:  Pulse and Blood Pressure Grading .............................................................................41  
Table 12:  Labo ratory Adverse Event Grading Scale  ..................................................................42  
Table 13:  Subject Disposition by Study Arm .............................................................................43  
Table 14:  Analysis Populations by Study Arm ...........................................................................44  
Table 15:  Dates of First Vaccination by Site and Study Arm .....................................................47  
Table 16:  Ineligibility Summary of Screen Failures  ...................................................................48  
Table 17:  Summary of Categorical Demographic and Baseline Characteristics by  Site ............49  
Table 18:  Summary of Continuous Demographic and Baseline Characteristics by Site ............50  
Table 19:  Summary of Categorical Demographic and Baseline Characteristics by 
Study Arm, All Enrolled Subjects  ..............................................................................51  
Table 20:  Summary of Continuous Demographic and Baseline Characteristics by 
Study Arm, All Enrolled Subjects  ..............................................................................52  
Table 21:  Summary of Subjects with Pre-Existing Medical Conditions by MedDRA System Organ Class and Study Arm  ..........................................................................53
 
Table 22:  Geometric Mean Percentage (GMP) of CD4+ T Cell Subsets Expressing 
Markers Alone or in Combination After M-001 Stimulation with 95% 
Confidence Intervals by Study Day and Study Arm, Per Protocol Population* .................................................................................................................54
 
Table 23:  Geometric Mean Percentage (GMP) of CD8+ T Cell Subsets  Expressing 
Markers Alone or in Combination After M-001 Stimulation with 95% Confidence Intervals by Study Day and Study Arm, Per Protocol 
Population* .................................................................................................................55
 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 27 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 24:  Geometric Mean Percentage (GMP) of CD4+ T Cell Subsets Expressing 
Markers Alone or in Combination After M-001 Stimulation with 95% 
Confidence Intervals by Study Day and Study Arm, Modified Intent- to-Treat 
Population* .................................................................................................................55  
Table 25:  Geometric Mean Percentage (GMP) Of CD8+ T Cell Subsets Expressing Markers Alone or in Combination After M- 001 Stimulation with  95% 
Confidence Intervals by Study Day and Study Arm, Modified Intent- to-Treat 
Population* .................................................................................................................55
 
Table 26:  Percentage of CD4+ T Cell Su bsets Expressing Markers Alone or in 
Combination After Seasonal Influenza A Antigen Stimulation with 95% 
Confidence Intervals by Study Day and Study Arm, Per Protocol Population ..........55  
Table 27:  Percentage of CD8+ T Cell Subsets Expressing Markers Alone or in 
Combination After Seasonal Influenza A Antigen Stimulation with 95% 
Confidence Intervals by Study Day and Study Arm, Per Protocol Population ..........55  
Table 28:  Percentage of CD4+ T Cell Subsets Expressing Markers Alone or in 
Combination After Pandemic Influenza A Antigen Stimulation with 95% 
Confidence Intervals by Study Day and Study Arm, Per Protocol Population ..........55  
Table 29:  Percentage of CD8+ T Cell Subsets Expressing Markers Alone or in 
Combination After Pande mic Influenza A Antigen Stimulation with 95% 
Confidence Intervals by Study Day and Study Arm, Per Protocol Population ..........55  
Table 30:  Summaries of Hemagglutination Inhibition Antibody Against 
A/Michigan/45/2015 X-275 (H1N1) by Study Day and Study Arm, Per 
Protocol Population ....................................................................................................56  
Table 31:  Summaries of Hemagglutination Inhibition Antibody Against 
A/Singapore/INFIMH-16-0019/2016 NIB-104(H3N2)-Guinea RBC by 
Study Day and Study Arm, Per Protocol Population ..................................................57  
Table 32:  Summaries of Hemagglutination Inhibition Antibody Against 
B/Colorado/6/2017 (B Victoria Lineage) by Study Day and Study Arm, Per 
Protocol Population ....................................................................................................57  
Table 33:  Summaries of Hemagglutination Inhibition Antibody Against 
B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day and Study Arm, 
Per Protocol Population ..............................................................................................57  
Table 34:  Summaries of Neutralizing Antibody Against A/Michigan/45/2015 X-275 
(H1N1) by Study Day and Study Arm, Per Protocol Population ...............................57  
Table 35:  Summaries of Neutralizing Antibody Against A/Singapore/INFIMH -16-
0019/2016 NIB-104(H3N2) by Study Day and Study Arm, Per Protocol Population ...................................................................................................................57
 
Table 36:  Summaries of Neutralizing Antibody Against B/Colorado/6/2017 (B Victoria Lineage) by Study Day and Study Arm, Per Protocol Population ...............57
 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 28 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 37:  Summaries of Neutralizing Antibody Against B/Phuket/3073/2013 (B 
Yamagata Lineage) by Study Day and Study Arm, Per Protocol Population ............57  
Table 38:  Percentage of Influenza- Specific CD4+ Cell Subsets Expressing Discrete 
Memory Markers (CCR7, CD45RO, and CD57) by Study Arm and Study Day, Per Protocol Population .....................................................................................58
 
Table 39:  Percentage of Influenza- Specific CD8+ Cell Subsets Expressing Discrete 
Memory Markers (CCR7, CD45RO, and CD57) by Study Arm and Study Day, Per Protocol Population .....................................................................................61
 
Table 40:  Percentage of Influenza- Specific CD4+ Cell Subsets expressing IL -4 or IL -
17 by Study Arm and Study Day, Per Protocol Population ........................................61  
Table 41:  Percentage of Influenza- Specific CD4+ Cell Subsets expressing T Follicular 
Helper Cells (CD4+, CXCR5+, PD -1+, IL -21+) by Study Arm and Study 
Day, Per Protocol Population .....................................................................................61  
Table 42:  Percentage of Influenza- Specific CD4+ Cell Subsets expressing T Follicular 
Regulatory Cells (CXCR5+, PD -1+, CD25+, CD127+) by Study Arm and 
Study Day, Per Protocol Population ...........................................................................61  
Table 43:  Percentage of Influenza- Specific CD4+ Cell Subsets expressing Tregs 
(CD25+, Foxp3+) by Study Arm and Study Day, Per Protocol Population ...............61  
Table 44:  Summaries of ELISA Antibody Against M -001 by Study Day and Study 
Arm, Per Protocol Population .....................................................................................62  
Table 45:  Overall Summary of Adverse Events*  .......................................................................63  
Table 46:  Adverse Events Occurring in 5% of Subjects in Any Study Arm by MedDRA System Organ Class and Preferred Term, and Study Arm  ........................65
 
Table 47:  Number and Percentage of Subjects Experiencing Solicited Events with 95% 
Confidence Intervals by Symptom, Dose, and Study Arm* .......................................66  
Table 48:  Comparison of the Proportion of Subjects Experiencing Solicited Events by Study Arm  ...................................................................................................................67
 
Table 49:  Number and Percentage of Subjects Experiencing Solicited Events by 
Symptom, Maximum Severity, Dose, and Study Arm* .............................................68  
Table 50:  Numb er and Percentage of Subjects Experiencing Solicited Events by 
Symptom, Severity, and Day Post Dosing, Group A: 1 mg M-001, Post First Vaccination  .................................................................................................................72
 
Table 51:  Number and Percentage of Subjects Experiencing Solicited Events by 
Symptom, Severity, and Day Post Dosing, Group A: 1 mg M-001, Post 
Second Vaccination  ....................................................................................................76  
Table 52:  Number and Percentage of Subjects Experiencing Solicited Events by 
Symptom, Severity, and Day Post Dosing, Group B: Placebo, Post First 
Vaccination  .................................................................................................................76  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 29 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 53:  Number and Percentage of Subjects Experiencing Solicited Events by 
Symptom, Severity, and Day Post Dosing, Group B: Placebo, Post Second 
Vaccination  .................................................................................................................76  
Table 54:  Number and Percentage of Subjects Experiencing Solicited Events for Dose 
1 Compared with Dose 2 by Study Arm .....................................................................77  
Table 55:  Summary of Unsolicited Adverse Events by MedDRA System Organ Class 
and Preferred Term, Dose Number, and Study Arm ..................................................78  
Table 56:  Unsolicited Adverse Events by MedDRA System Organ Class and Preferred Term, Maximum Severity, Relationship, and Study Arm* ........................................79
 
Table 57:  Related Unsolicited Adverse Events Within 21 Days Post Dosing by 
MedDRA System Organ Class and Preferred Term, Dose, and Study Arm ..............80  
Table 58:  Listing of Serious Adverse Events* ...........................................................................81  
Table 59:  Listing of Abnormal Laboratory Results - Chemistry  ................................................83  
Table 60:  Listing of Abnormal Laboratory Results - Hematology  .............................................84  
Table 61:  Laboratory Results by Parameter, Maximum Severity, S tudy Day, and Study 
Arm ‚Äì Any Chemistry Parameter  ...............................................................................85  
Table 62:  Laboratory Results by Parameter, Study Day, and Study Arm ‚Äì Alanine 
Aminotransferase  ........................................................................................................86  
Table 63:  Laboratory Results by Parameter, Study Day, and Study Arm ‚Äì Total 
Bilirubin  ......................................................................................................................86  
Table 64:  Laboratory Results by Parameter, Study Day, and Study Arm ‚Äì Creatinine  .............86  
Table 65:  Laboratory Summary Statistics by Parameter, Study Day, and Study Arm ‚Äì 
Alanine Aminotransferase*  ........................................................................................87  
Table 66:  Laboratory Summary Statistics by Parameter, Study Day, and Study Arm ‚Äì 
Total Bilirubin*  ..........................................................................................................87  
Table 67:  Laboratory Summary Statistics by Parameter, Study Day, and Study Arm ‚Äì 
Creatinine*  ..................................................................................................................87  
Table 68:  Laboratory Results by Parameter, Maximum Severity, Study Day, and Study Arm ‚Äì Any Hematology Parameter  ............................................................................88
 
Table 69:  Laboratory Results by Parameter, Maximum Severity, Study Day, and Study 
Arm ‚Äì White Blood Cells  ...........................................................................................89  
Table 70: Laboratory Results by Parameter, Maximum Severity, Study Day, and Study Arm ‚Äì Hemoglobin  .....................................................................................................89
 
Table 71:  Laboratory Results by Parameter, Maximum Severity, Study Day, and Study 
Arm ‚Äì Platelets  ...........................................................................................................89  
Table 72:  Laboratory Summary Statistics by  Parameter, Study Day, and Study Arm ‚Äì 
White Blood Cells*  .....................................................................................................90  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 30 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 73:  Laboratory Summary Statistics by Parameter, Study Day, and Stu dy Arm ‚Äì 
Hemoglobin* ..............................................................................................................90  
Table 74:  Laboratory Summary Statistics by Parameter, Study Day, and Study Arm ‚Äì 
Platelets*  .....................................................................................................................90  
Table 75:  Vital Signs by Assessment, Maximum Severity, Study Day, and Study Arm 
‚Äì Any Assessment  .......................................................................................................91  
Table 76:  Vital Signs by Assessment, Maximum Severity, Study Day, and Study Arm 
‚Äì Systolic Blood Pressure ...........................................................................................92  
Table 77:  Vital Signs by Assessment, Maximum Severity, Study Day, and Study Arm 
‚Äì Diastolic Blood Pressure ..........................................................................................92  
Table 78:  Vital Signs by Assessment, Maximum Severity, Study Day, and Study Arm ‚Äì Oral Temperature  .....................................................................................................92
 
Table 79:  Vital Signs by Assessment, Maximum Severity, Study Day, and Study Arm 
‚Äì Pulse .........................................................................................................................92  
Table 80:  Number and Percentage of Subjects with Prior and Concurrent Medications 
by WHO Drug Classification and Study Arm  ............................................................93  
 
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 31 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  9.1 Overall Study Design  and Plan Description 
Table 1: Study Design  
Study Arm Dose 1  
Day 1  Dose 2  
Day 22  Dose 3  
Day 172  
A (n=60)  1 mg M -001 1 mg M -001 IIV4  
B (n=60)  Placebo  Placebo  IIV4  
Statistical Analysis Plan - DMID Protocol: 14-0112 Version 1.0 
09September2019 
- 32 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  9.5.1 Efficacy/Immunogenicity and Safety Measurements Assessed and Flow Chart  
Table 2: Schedule of Study Procedures  
Stud y Visit (V) 01 02 03 04 05 06 07 08 09 10 11 12 
Stud y Day 1 9 15 22 30 36 43 78 172 186 200 200+ 
Visit Windows   (+2) (+2) (+2) (+2) (+2) (+7) (+7) 142-202 (+3) (+7) (+14)  
Sign Consent Form1 X            
Assess eligibility  X   X     X    
Collect demographic information  X            
Review M edical History X  X X  X X X X X X X 
Concomi tant meds  X X X X X X X X7 X7 X7 X7 X7 
Vital signs2 X {X} {X} X {X} {X} {X} {X} X {X} {X}  
Height, Weight  X            
Targeted Physical Exam  {X} {X} {X} {X} {X} {X} {X} {X} {X} {X} {X}  
Review contraception/ Counseling3 X X X X X X X X X X   
Pregnanc y Test2,4 X   X     X    
Blood - Safety Labs (10 mL)  X X   X        
Blood ‚Äì Antibody Assays (10 -20 mL)  X   X   X X X*  X*  
Blood ‚Äì PBMCs (40 -60 mL)  X=  X   X X= X X X X  
Randomization  X            
AE/SAE Assessment2# X X X X X X X X X X X X 
Vaccinati on4 X5   X5     X    
Evaluate vaccination site  X X  X X        
Postvaccination procedures6 X   X         
Review Memory Aid Data   X   X        
Blood volume (mL)  80 10 40 10 10 40 70 50 60 40 60  
{ } required at this visit only if clinically indicated  
1Consent process completed and form signed before any study -related procedures are conducted.  
2Vital signs include blood pressure, pulse, and oral temperature.  On vaccination visits, these items should be completed prior to vaccination.  
3Counseling on a voidance of pregnancy for women of childbearing potential.  
4Urine or serum pregnancy test must be negative and be completed within 24 hours prior to vaccination for women of childbearing potential.   
5All subjects will be observed for a minimum of 20 minut es following vaccination.  
6Post-vaccination procedures will include documentation of any reactogenicity during the observation period and any AEs/SAEs post -vaccination, as well as provision of Memory Aid and instructions on 
completion.  
 7 Concomitant med ications (vaccines only) will be recorded on the appropriate data collection form after Visit 7 through the end of the study.  
+Visit 12 will occur as a phone call only if visit 11 occurs prior to Study Day 200.  
*20 mL of blood will be collected for antibod y assays on these days; 10 mL will be collected on other days of collection for antibody assays  
=60 mL of blood will be collected for PBMCs on these days; 40 mL will be collected on other days of PBMC collection  
#AEs will be limited to SAEs after 21 days a fter M -001 study vaccinations.  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 33 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  9.7.1 Sample Size  
Table 3: Power (%) to Detect Safety Events  
Event  
Frequency  Single Study Arm 
N=60  Two Study Arm s 
N=120 
‚â•10%  
Very Common  99.8 >99.9  
‚â•1%  
Common  45.3 70.1 
‚â•0.1%  
Uncommon  5.8 11.3 
‚â•0.01%  
Rare  <1 1.2 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 34 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 4: Precision of Binomial Confidence Intervals  
 
N 95% CI  
Single Study Arm  60 (36.8,  63.2)  
Two Study Arm s 120 (40.7, 59.3)  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 35 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 5: Power Analysis for Primary Immunogenicity Endpoint 
GMP e/GMT c 
{fold -change}  log 10 (GMP M)-log 10 (GMP c) 
{log-difference}  Std Dev  
log 10 (GMP)  Power (N = 60)  Power (N=54)  
10% drop out  
1.5 0.18 0.25 97 96 
0.50 49 45 
0.75 26 23 
2 0.30 0.25 >99 >99 
0.50 90 87 
0.75 58 54 
3 0.48 0.25 >99 >99 
0.50 >99 99 
0.75 93 90 
4 0.60 0.25 >99 >99 
0.50 >99 >99 
0.75 99 98 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 36 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  10.2 Protocol Deviations 
Table 6: Distribution of Protocol Deviations by Category, Type, and Study Arm  (All Enrolled 
Subjects)  
[Implementation Note: Include all deviation types collected in the study, even if not listed here; do not include 
categories with zero deviations reported for All Subjects .] 
Category  Deviation Type  Group A: 1 mg M -
001  
(N=X ) Group B:  
Placebo  
(N=X ) All Subjects  
(N=X ) 
No. of 
Subj.  No. of 
Dev.  No. of 
Subj.  No. of 
Dev.  No. of 
Subj.  No. of 
Dev.  
Eligibility/enrollment Any type        
 Did not meet inclusion criterion x x x x x x 
 Met exclusion criterion        
 ICF not signed prior to study procedures        
 Other        
Treatment administration 
schedule  Any type        
 Out of window visit        
 Missed visit/visit not conducted        
 Missed treatment adminis tration        
 Delayed treatment administration        
 Other        
Follow -up visit schedule  Any type        
 Out of window visit        
 Missed visit/visit not conducted        
 Other        
Protocol procedure/assessment  Any type        
 Incorrect versi on of ICF signed        
 Blood not collected        
 Too few aliquots obtained        
 Specimen result not obtained        
 Required procedure not conducted       
 Required procedure done incorrectly        
 Study product temperature excursion        
 Specimen temperature excursion        
 Other        
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 37 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Category  Deviation Type  Group A: 1 mg M -
001  
(N=X ) Group B:  
Placebo  
(N=X ) All Subjects  
(N=X ) 
No. of 
Subj.  No. of 
Dev.  No. of 
Subj.  No. of 
Dev.  No. of 
Subj.  No. of 
Dev.  
Treatment administration  Any type        
 Required procedure done incorrectly        
 Study product temperature excursion        
 Other        
Blinding policy/procedure  Any type        
 Treatment unblinded        
 Other        
Note: N=Number of subjects enrolled.  
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 38 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  12.2.2 Displays of Adverse Events 
Table 7: Subjective Systemic Reactogenicity Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3) 
Feverishness 
(Chills/Shivering/Sweating)  No interference with 
daily activity  Some interference with daily 
activity  Significant interference, 
prevents daily activity  
Fatigue  No interference with 
daily activity  Some interference with daily 
activity  Significant interfer ence, 
prevents daily activity  
Malaise  No interference with 
daily activity  Some interference with daily 
activity  Significant interference, 
prevents daily activity  
Myalgia*  No interference with 
daily activity  Some interference with daily 
activity  Significant interference, 
prevents daily activity  
Arthralgia*  No interference with 
daily activity  Some interference with daily 
activity  Significant interference, 
prevents daily activity  
Headache No interference with 
daily activity  Some interfere nce with daily 
activity  Significant interference, 
prevents daily activity  
Nausea  No interference with 
daily activity  Some interference with daily 
activity  Significant interference, 
prevents daily activity  
* Not at injection site.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 39 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 8: Quantitative Systemic Reactogenicity Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral‚Ä† 38.0¬∞C ‚Äì 38.4¬∞C  
100.4¬∞F ‚Äì 101.1¬∞F  38.5¬∞C ‚Äì 38.9¬∞C  
101.2¬∞F ‚Äì 102.0¬∞F  >38.9¬∞C  
>102.0¬∞F  
Note: Oral temperature assessed on Day 1 prior to the first primary series study vaccination will be considered as baseline.  
* A fever can be considered not related to the study product if an alternative etiology can be documented.  
‚Ä† Subjects must not eat or drin k anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 40 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 9: Injection Site Reactogenicity Grading  
Injection Site Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain ‚Äì experienced without 
touching the injection site 
(spontaneous discomfort)  Subject is aware of pain, but it 
does not interfere with daily 
activity,  and no pain 
medication is taken  Subject is aware of pain; there is 
interference with daily activity  or 
it requ ires repeated use of a non -
narcotic pain reliever for >24 
hours  Subject is aware of pain, 
and it prevents daily 
activity or requir es any use 
of a narcotic pain reliever  
Tenderness ‚Äì hurts only 
when injection site is 
touched or the arm is 
moved  The area im mediately 
surrounding the injection site 
hurts only when touched or 
with arm motion, and it does 
not interfere with daily activity  The area immediately surrounding 
the injection site hurts when 
touched or with arm motion, and 
it interferes with daily activ ity The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
prevents daily activity  
Pruritus  Does not interfere with daily 
activity  Interferes with daily activity  Prevents daily activity  
Ecchymosis*  Does not int erfere with daily 
activity  Interferes with daily activity  Prevents daily activity  
Erythema*  Does not interfere with daily 
activity  Interferes with daily activity  Prevents daily activity  
Induration/Edema* Does not interfere with daily 
activity  Interferes with daily activity  Prevents daily activity  
*Will be also measured in mm but size will not be used as halting criteria.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 41 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 10: Injection Site Reactogenicity Measurements  
Injection Site Reaction  Small  Medium  Large 
Ecchymosis *  <20 mm 20 mm ‚Äì 50 mm  >50 mm 
Erythema*  <20 mm 20 mm ‚Äì 50 mm  >50 mm 
Induration /Edema*  <20 mm 20 mm ‚Äì 50 mm  >50 mm 
* Will not be used as halting criteria.  
 
Table 11: Pulse and Blood Pressure Grading  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute 45 ‚Äì 49 40 ‚Äì 44 <40 
Tachycardia - beats per minute 116 ‚Äì 130 131 ‚Äì 155 >155  
Hypotension (systolic) mm Hg  80 ‚Äì 84 75 ‚Äì 79 <75 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 42 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  12.4.1 Individual Laboratory Measurements and Abnormal Laboratory Values 
Table 12: Laboratory Adverse Event Grading Scale 
Parameter Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  
Hematology  
WBC 103/¬µL (Decrease)  2.5 ‚Äì 3.9 1.5 ‚Äì 2.4 <1.5 
WBC 103/¬µL (Increase)  10.6 ‚Äì 15.0 15.1 ‚Äì 20.0 >20.0  
Hgb g/dL (Decrease) (Female)  10.1 ‚Äì 11.4 8.5 ‚Äì 10 <8.5 
Hgb g/dL (Decrease) (Male)  11.0 ‚Äì 12.4 9.5 ‚Äì 10.9 <9.5 
Platelets 103/¬µL (Decrease)  125 ‚Äì 139 100 ‚Äì 124 <100  
Platelets 103/¬µL (Increase)  416 ‚Äì 550 551‚Äì 750 >750  
Chemistry  
ALT IU/L (Increase) (Female)  44 ‚Äì 100 101 ‚Äì 200 >200  
ALT IU/L (Increase) (Male)  61 ‚Äì 138 139 ‚Äì 275 >275  
Total Bilirubin mg/dL (Increase) ‚Äì when 
accompanied by any increase in ALT  1.30 ‚Äì 1.59 1.60 ‚Äì 1.80 >1.80  
Total Bilir ubin mg/dL (Increase) ‚Äì when ALT is 
normal  1.30 ‚Äì 1.89 1.90 ‚Äì 2.40 >2.40  
Creatinine mg/dL (Increase) (Female)  1.1 ‚Äì 1.7 1.8 ‚Äì 2.0 >2.0 
Creatinine mg/dL (Increase) (Male)  1.4 ‚Äì 1.7 1.8 ‚Äì 2.0 >2.0 
Note: Clinical laboratory evaluations assessed at the enro llment visit (Visit 01) will be considered as baseline.  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 43 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.1 Description of Study Subjects  
14.1.1 Disposition of Subjects  
Table 13: Subject Disposition by Study Arm  
Subject  
Disposition  Group A: 1 mg M -001  
(N=X)  Group B: Placebo  
(N=X)  All Subjects  
(N=X)  
n % n % n % 
Screened  -- -- -- -- x -- 
Enrolled/Randomized  x 100 x 100 x 100 
Received Study Vaccination  x xx x xx x xx 
Received first 2 doses  x xx x xx x xx 
Received All Scheduled Study Vaccinationsa x xx x xx x xx 
Completed  PBMC  Blood Draw at Study Day 
43 (Visit 0 7) x xx x xx x xx 
Completed Follow -up (Study Day 200)a  x xx x xx x xx 
Completed Final  PBMC  Blood Draw (Day 
200 / Visit 11)  x xx x xx x xx 
Note: N=Number of subjects enrolled.  
a Refer to Listing 2 for reasons subjects discontinued or terminated early.  
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 44 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 14: Analysis Populations by Study Arm  
Analysis Populations  Reason Subjects Excluded  Group A:  
1 mg M -001  
(N=X)  Group B:  
Placebo  
(N=X)  All Subjects  
(N=X)  
n % n % % n 
Safety Analysis Population  Any Reason  x xx x xx x xx 
 No Study Vaccination Received        
Modified Intent -to-Treat Population  Any Reason        
 No Study Vaccination Received        
 Ineligible at Baseline        
 No Post -Vaccination Res ults Available        
Per Protocol , Day 9  Any Reason        
 No Study Vaccination Received        
 Ineligible at Baseline        
 No Day 9 Result Reported by Lab       
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 9 Visit Out of Window        
Per Protocol , Day 15  Any Reason        
 No Study Vaccination Received        
 Ineligible at Baseline        
 No Day 15 Result Reported by Lab       
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 15 Visit Out of Window        
Per Protocol , Day 22  Any Reason        
 No Study Vaccination Received        
 Ineligible at Baseline        
 No Day 22 Result Reported by Lab       
 Receipt of Non -Study Vaccination        
 Receipt of I mmunosuppressive Medication        
 Day 22 Visit Out of Window        
Per Protocol , Day 30  Any Reason        
 No Study Vaccination Received        
 Study Vaccination 2 Not Received        
 Study Vaccination 2 Out of Window        
 Ineligible at Baseline        
 No Day 30 Result Reported by Lab       
 Receipt of Non -Study Vaccination        
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 45 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 14: Analysis Populations by Study Arm (Continued)  
Analysis Populations  Reason Subjects Excluded  Group A:  
1 mg M -001  
(N=X)  Group B:  
Placeb o 
(N=X)  All Subjects  
(N=X)  
n % n % % n 
 Receipt of Immunosuppressive Medication        
 Day 30 Visit Out of Window        
Per Protocol , Day 36  (Primary 
Endpoint)  Any Reason        
 No Study Vaccination Received        
 Study Vaccination 2 Not Received        
 Study Vaccination 2 Out of Window        
 Ineligible at Baseline        
 No Day 36  Result Reported by Lab       
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 36  Visit Out of Window        
Per Protoco l, Day 43   Any Reason        
 No Study Vaccination Received        
 Study Vaccination 2 Not Received        
 Study Vaccination 2 Out of Window        
 Ineligible at Baseline        
 No Day 43 Result Reported by Lab       
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 43 Visit Out of Window        
Per Protocol , Day 78  Any Reason        
 No Study Vaccination Received        
 Study Vaccination 2 Not Received        
 Study Vaccination 2 Out of Window        
 Ineligible at Baseline        
 No Day 78 Result Reported by Lab       
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 78 Visit Out of Window        
Per Protocol , Day 172 Any Reason        
 No Study Vaccination Received        
 Study Vaccination 2 Not Received        
 Study Vaccination 2 Out of Window        
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 46 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 14: Analysis Populations by Study Arm (Continued)  
Analysis Populations  Reason Subjects Excluded  Group A:  
1 mg M -001  
(N=X)  Group B : 
Placebo  
(N=X)  All Subjects  
(N=X)  
n % n % % n 
 Ineligible at Baseline        
 No Day 172 Result Reported by Lab        
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 172 Visit Out of Window        
Per Pro tocol , Day 186 Any Reason        
 No Study Vaccination Received        
 Study Vaccination 3 Not Received        
 Study Vaccination 3 Out of Window        
 Study Vaccination 2 Not Received        
 Study Vaccination 2 Out of Window        
 Ineligible at Base line       
 No Day 186 Result Reported by Lab        
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 186 Visit Out of Window        
Per Protocol , Day 200 Any Reason        
 No Study Vaccination Received        
 Study Vaccination 3 Not Received        
 Study Vaccination 3 Out of Window        
 Study Vaccination 2 Not Received        
 Study Vaccination 2 Out of Window        
 Ineligible at Baseline        
 No Day 200 Result Reported by Lab        
 Receipt of Non -Study Vaccination        
 Receipt of Immunosuppressive Medication        
 Day 200 Visit Out of Window        
Note: N=Number of subjects enrolled.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 47 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 15: Dates of First Vaccination by Site and Study A rm 
[Implemen tation Note: Weekly intervals for dosing date should be displayed. The earliest date should be the 
FSFV over all sites.]  
 Site 1: BCM  Site 2: Iowa  Site 3: CCHMC  
Dates of Dosing  Group A: 1 mg 
M-001 
(N=X)  Group B: 
Placebo  
(N=X)  Group A: 1 mg 
M-001 
(N=X)  Group B: 
Placebo  
(N=X)  Group A: 1 mg 
M-001 
(N=X)  Group B:  
Placebo  
(N=X)  
Dose 1  
Total (Entire period of 
enrollment)        
DDMMMYYYY-
DDMMMYYYY x x x x x x 
Dose 2  
Total (Entire period of 
enrollment)        
DDMMMYYYY-
DDMMMYYYY x x x x x x 
Dose 3  
Total (Entire period of 
enrollment)        
DDMMMYYYY-
DDMMMYYYY x x x x x x 
Notes: N=Number of subjects enrolled.  
BCM=Baylor College of Medicine, Iowa=University of Iowa, CCHMC=Cincinnati Children‚Äôs Hospital Medical Center  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 48 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 16: Ineligibility Summary of Screen Failures  
Inclusion/Exclusion Category  Inclusion/Exclusion Criterion  na %b 
Inclusion and Exclusion  Number of subjects failing any eligibility criterion  x 100 
Inclusion  Any inclusion criterion  x xx 
 Systolic blood  pressure is within the per protocol range  x xx 
 Diastolic blood pressure is within the per protocol range  x xx 
 Are able to understand and comply with planned study procedures and be available 
for all study visits  x xx 
 Are in good health  x xx 
 Women of childbearing potential must use an acceptable method of contraception 
from 30 days prior to vaccination until 60 days after the second dose of M -001 or 
placebo  x xx 
 Women of childbearing potential must use an acceptable method of contraception 
from 30  days prior to receipt of IIV vaccination, and must plan to use until 28 days 
after the IIV  x xx 
Exclusion  Any exclusion criterion  x xx 
 Have any medical disease or condition that, in the opinion of the site PI or 
appropriate sub -investigator, is a contraindication to study participation  x xx 
 Have an acute illness, as determined by the site PI or appropriate sub -investigator, 
within 72 hours prior to study vaccination  x xx 
 Have signs or symptoms that could confound or confuse assessment of study 
vacci ne reactogenicity  x xx 
 Plan to travel outside the U.S. (continental U.S., Hawaii, and Alaska) in the time 
between the first study vaccination and 21 days after the last study vaccination  x xx 
 Have been hospitalized for psychiatric illness, history of s uicide attempt, or 
confinement for danger to self or others within 10 years prior to study vaccination  x xx 
 Blood donation or planned blood donation within 30 days prior to the study 
vaccination through 30 days after the last blood drawn for this study x xx 
a More than one criterion may be marked per subject.  
b Denominator for percentages is the total number of screen failures.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 49 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.1.2 Demographic Data by Study Group 
Table 17: Summary of Categorical Demographic an d Baseline Characteristics by Site 
Variable  Characteristic  Site 1: BCM 
(N=X)  Site 2: Iowa 
(N=X)  Site 3:  CCHMC      
(N=X)  All Subjects  
(N=X)  
n % n % n % n % 
Sex  Male x xx x xx x xx x xx 
 Female          
Ethnicity  Not Hispanic or Latino  x xx x xx x xx x xx 
 Hispanic or Latino          
 Not Reported          
 Unknown         
Race  American Indian or Alaska Native x xx x xx x xx x xx 
 Asian          
 Native Hawaiian or Other Pacific 
Islander      
    
 Black or African American          
 White          
 Multi-Racial          
 Unknown         
Prior Seasonal 
Influenza Vaccination  2016- 17 only      
    
 2017- 18 only          
 Both         
 Neither          
 Unknown         
Age 18-29         
 30-39         
 40-49         
BMI <30         
 ‚â•30         
Notes: N=Number of subjects enrolled.  
BCM=Baylor College of Medicine, Iowa=University of Iowa, CCHMC=Cincinnati Children‚Äôs Hospital Medical C enter  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 50 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 18: Summary of Continuous Demographic and Baseline Characteri stics by Site  
Variable  Statistic Site 1: BCM 
(N=X)  Site 2: Iowa 
(N=X)  Site 3: CCHMC  
(N=X)  All Subjects  
(N=X)  
Age (Years)  Mean  xx xx xx xx 
 Standard Deviation  xx xx xx xx 
 Median  xx xx xx xx 
 Minimum  x x x x 
 Maximum  x x x x 
BMI Mean  xx xx xx xx 
 Standard Deviation  xx xx xx xx 
 Median  xx xx xx xx 
 Minimum  x x x x 
 Maximum  x x x x 
Note s: N=Number of subjects enrolled.  
BCM=Baylor College of Medicine , Iowa=University of Iowa , CCHMC=Cincinnati Children‚Äôs Hospital Medical Center  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 51 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 19: Summary of Categorical Demographic and Baseline Characteristics by Study Arm , All 
Enrolled Subjects  
Variable  Characteristic  Group A: 1 mg M -001 
(N=X)  Group B: Placebo  
(N=X)  All Subjects  
(N=X)  
n % n % n % 
Sex  Male x xx x xx x xx 
 Female        
Ethnicity  Not Hispanic or Latino  x xx x xx x xx 
 Hispanic or Latino        
 Not Reported        
 Unknown       
Race  American Indian or Alaska Native x xx x xx x xx 
 Asian        
 Native Hawaiian or Other Pacific 
Islander        
 Black or African American        
 White        
 Multi-Racial        
 Unknown       
Prior Seasonal Influenza 
Vaccination  (2017 -2018)  2016- 17 only        
 2017- 18 only        
 Both       
 Neither        
 Unknown       
Age  18-29       
 30-39       
 40-49       
BMI <30       
 ‚â•30       
Note: N=Number of subjects enrolled.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 52 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 20: Summary of Continuous Demographic and Baseline Characteristics by Study Arm , All 
Enrolled Subjects  
Variable  Statistic Group A: 1 mg  M-001 
(N=X)  Group B: Placebo  
(N=X)  All Subjects  
(N=X)  
Age (years ) Mean  xx xx xx 
 Standard Deviation  xx xx xx 
 Median  x x x 
 Minimum  x x x 
 Maximum  x x x 
BMI Mean  xx xx xx 
 Standard Deviation  xx xx xx 
 Median  x x x 
 Minimum  x x x 
 Maximum  x x x 
Note: N= Number of subjects enrolled.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 53 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.1.3 Prior and Concurrent Medical Conditions  
Table 21: Summary of Subjects with Pre -Existing Medical Conditions by MedDRA  System Organ Class and Study A rm 
MedDRA System Organ Class  Group A: 1 mg M -001 
(N=X)  Group B: Placebo  
(N=X)  All Subjects  
(N=X)  
n % n % n % 
Any SOC  x xx x xx x xx 
[SOC 1]        
[SOC 2]        
       
       
Note s: N=Number of subjects enrolled  
n = Number of subjects reporting medical history within the specified SOC. A subject is only counted once per SOC.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 54 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.2 Efficacy/Immunogenicity Data 
Table 22: Geometric Mean Percentage (GMP) of CD4+ T Cell Subsets  Expressing Markers Alone 
or in Combination After M-001 Stimulation with 95% Confidence Intervals by Study 
Day and Study Arm, Per Protocol Population* 
Study 
Day Perforin  CD107a  IFN-
Œ≥ TNF -
Œ± IL2 Group A: 1 mg M -001 Group B: Placebo  
p-valuex 
n GMP  95% CI  n GMP  95% CI  
Primary Endpoint  
Day 36  + + + + + x x.x x.x, x.x  x x.x x.x, x.x   
 + + + + - x x.x x.x, x.x  x x.x x.x, x.x   
 + + + - + x x.x x.x, x.x  x x.x x.x, x.x   
 + + + - - x x.x x.x, x.x  x x.x x.x, x.x   
 + + - + + x x.x x.x, x.x  x x.x x.x, x.x   
 + + - + - x x.x x.x, x.x  x x.x x.x, x.x   
 + + - - + x x.x x.x, x.x  x x.x x.x, x.x   
 + + - - - x x.x x.x, x.x  x x.x x.x, x.x   
 + - + + + x x.x x.x, x.x  x x.x x.x, x.x   
 + - + + - x x.x x.x, x.x  x x.x x.x, x.x   
 + - + - + x x.x x.x, x.x  x x.x x.x, x.x   
 + - + - - x x.x x.x, x.x  x x.x x.x, x.x   
 + - - + + x x.x x.x, x.x  x x.x x.x, x.x   
 + - - + - x x.x x.x, x.x  x x.x x.x, x.x   
 + - - - + x x.x x.x, x.x  x x.x x.x, x.x   
 + - - - - x x.x x.x, x.x  x x.x x.x, x.x   
 - + + + + x x.x x.x, x.x  x x.x x.x, x.x   
 - + + + - x x.x x.x, x.x  x x.x x.x, x.x   
 - + + - + x x.x x.x, x.x  x x.x x.x, x.x   
 - + + - - x x.x x.x, x.x  x x.x x.x, x.x   
 - + - + + x x.x x.x, x.x  x x.x x.x, x.x   
 - + - + - x x.x x.x, x.x  x x.x x.x, x.x   
 - + - - + x x.x x.x, x.x  x x.x x.x, x.x   
 - + - - - x x.x x.x, x.x  x x.x x.x, x.x   
 - - + + + x x.x x.x, x.x  x x.x x.x, x.x   
 - - + + - x x.x x.x, x.x  x x.x x.x, x.x   
 - - + - + x x.x x.x, x.x  x x.x x.x, x.x   
 - - + - - x x.x x.x, x.x  x x.x x.x, x.x   
 - - - + + x x.x x.x, x.x  x x.x x.x, x.x   
 - - - + - x x.x x.x, x.x  x x.x x.x, x.x   
 - - - - + x x.x x.x, x.x  x x.x x.x, x.x   
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 55 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Study 
Day Perforin  CD107a  IFN-
Œ≥ TNF -
Œ± IL2 Group A: 1 mg M -001 Group B: Placebo  
p-valuex 
n GMP  95% CI  n GMP  95% CI  
 - - - - - x x.x x.x, x.x  x x.x x.x, x.x   
 +  +/- +/- +/- +/- x x.x x.x, x.x  x x.x x.x, x.x   
 +/- + +/- +/- +/- x x.x x.x, x.x  x x.x x.x, x.x   
 +/- +/- + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x   
 +/- +/- +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x   
 +/- +/- +/- +/- + x x.x x.x, x.x  x x.x x.x, x.x   
Exploratory Endpoint s 
Repeat for Baseline, Day 15, Day 43, Day 78, Day 172, Day 186, and Day 200 without p-value column.  
Note s: N = number of subjects in Per Protocol population . 
xWald test from Poisson regression used to compare groups.  
95% CIs calculated via 10,000 bootstrap samples . 
 
Tables with similar format: 
[Implementation Note: Do not include p-value column for Tables 28-31, and only include it for Day 36 for 
Tables 25 -27. Include rows  for any perforin, any CD107a, any IFN- Œ≥, any TNF -Œ±, and any IL2.] 
Table 23: Geometric Mean Percentage (GMP) of CD8+ T Cell Subsets  Expressing Markers Alone 
or in Combination After M-001 Stimulation wit h 95% Confidence Intervals by Study 
Day and Study Arm, Per Protocol Population*  
Table 24: Geometric Mean Percentage (GMP) of CD4+ T Cell Subsets  Expressing Markers Alone 
or in Combination After M-001 Stimulation with 95% Confidence Intervals by Study Day and Study Arm, Modified Intent -to-Treat Population * 
Table 25: Geometric Mean Percentage (GMP) Of CD8+ T Cell Subsets  Expressing Markers Alone 
or in Combination After M-001 Stimulation with 95% Confidence Intervals by Study Day and Study Arm, Modified Intent -to-Treat Population *  
Table 26: Percentage of CD4+ T Cell Subsets  Expressing Markers Alone or in Combination After 
Seasonal Influenza A Antigen Stimulation with 95% Confidence Intervals by Study Day and Study Arm, Per Protocol Population  
Table 27: Percentage of CD8+ T Cell Subsets  Expressing Markers Alone or in Combination After 
Seasonal Influenza A An tigen Stimulation with 95% Confidence Intervals by Study Day 
and Study Arm, Per Protocol Population  
Table 28: Percentage of CD4+ T Cell Subsets  Expressing Markers Alone or in Combination After 
Pandemic Influenza A Antigen Stimulation with 95% Confidence Intervals by Study Day and Study Arm, Per Protocol Population  
Table 29: Percentage of CD8+ T Cell Subsets  Expressing Markers Alone or in Combination After 
Pandemic Influenza A Antigen Stimulation with 95% Confidence Intervals by Study Day and Study Arm, Per Protocol Population  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 56 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 30: Summaries of Hema gglutination Inhibition Antibody Against A/Michigan/45/2015 X-275 
(H1N1 ) by Study Day and Study Arm , Per Protocol  Population 
 Group A: 1 mg M -001 
(N=X)  Group B: Placebo  
(N=X)  
Day 1   
 n x x 
 GMT (95% CI) xxx.x(xxx.x,xxx.x)  xxx.x(xxx.x,xxx.x)  
 Titer ‚â• 1:40 - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
Day 22    
 n  x x 
 GMT (95% CI) xxx.x(xxx.x,xxx.x)  xxx.x(xxx.x,xxx.x)  
 Seroconversion - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
 Titer ‚â• 1:40 - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
Day 43    
 n  x x 
 GMT (95% CI) xxx.x(xxx.x,xxx.x)  xxx.x(xxx.x,xxx.x)  
 Seroconversion - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
 Titer ‚â• 1:40 - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
Day 172   
 n  x x 
 GMT (95% CI) xxx.x(xxx.x,xxx.x)  xxx.x(xxx.x,xxx.x)  
 Seroconversion - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
 Titer ‚â• 1:40 - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
Day 200   
 n  x x 
 GMT (95% CI) xxx.x(xxx.x,xxx.x)  xxx.x(xxx.x,xxx.x)  
 Seroconversion - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
 Titer ‚â• 1:40 - %(95% CI) x.x (x.x, x.x)  x.x (x.x, x.x)  
Note: N=Number of subjects in  Per Protocol  population.  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 57 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Tables with similar format: 
Table 31: Summaries of Hemagglutination Inhibition Antibody Against A/Singapore/INFIMH -16-
0019/2016 NIB-104(H3N2)-Guinea RBC by Study Day and Study Arm, Per Protocol 
Population 
Table 32: Summaries of Hemagglutination Inhibition Antibody Against B/Colorado/6/2017 (B 
Victoria Lineage) by Study Day and Study Arm, Per Protocol  Population  
Table 33: Summaries of Hemagglutination Inhibition Antibody Against B/Phuket/3073/2013 (B 
Yamagata Lineage) by Study Day and Study Arm, Per Protocol  Population 
Table 34: Summaries of Neutralizing Antibody Against A/Michigan/45/2015 X-275 (H1N1) by 
Study Day and Study A rm, Per Protocol  Population  
Table 35: Summaries of Neutralizing Antibody Against A/Singapore/IN FIMH -16-0019/2016 NIB-
104(H3N2) by Study Day and Study Arm, Per Protocol Population 
Table 36: Summaries of Neutralizing Antibody Against B/Colorado/6/2017 (B Victoria Lineage) by 
Study Day and Study A rm, Per Protocol  Population  
Table 37: Summaries of Neutralizing Antibody Against B/Phuket/3073/2013 (B Yamagata Lineage) 
by Study Day and Study Arm, Per Protocol  Population 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 58 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 38: Percentage of Influenza -Specific CD4+  Cell Subsets Expressing Discrete Memory 
Markers ( CCR7, CD45RO, and CD57 ) by Study Arm  and Study Day, Per Protocol  
Population 
Study Day  CCR7  CD45RO  CD57  Group A: 1 mg M-001 Group B: Placebo  
n GMP  95% CI  n GMP  95% CI  
Baseli ne + + + x x.x x.x, x.x  x x.x x.x, x.x  
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x.x  x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x  
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x.x x.x, x.x  x x.x x.x, x.x  
Day 15  + + + x x.x x.x, x.x  x x.x x.x, x.x  
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x.x  x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x  
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x.x x.x, x.x  x x.x x.x, x.x  
Day 36  + + + x x.x x.x, x.x  x x.x x.x, x.x  
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x.x  x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x  
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x.x x .x, x.x  x x.x x.x, x.x  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 59 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 38: Percentage of Influenza -Specific CD4+ Cell Subsets Expressing Discrete Memory 
Markers ( CCR7, CD45RO, and CD57 ) by Study Arm and Study Day, Per Protocol 
Population (Continued)  
Study Day  CCR7  CD45RO  CD57  Group A: 1 mg M -001 Group B: Placebo  
n GMP  95% CI  n GMP  95% CI  
Day 43  + + + x x.x x.x, x.x  x x.x x.x, x.x  
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x.x  x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x  
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x.x x.x, x.x  x x.x x.x, x.x  
Day 78  + + + x x.x x.x, x.x  x x.x x.x, x.x  
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x.x  x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x  
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x.x x.x, x.x  x x.x x.x, x.x  
Day 172  + + + x x.x x.x, x.x  x x.x x.x, x.x  
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x. x x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x  
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x.x x.x, x.x  x x.x x.x, x.x  
Day 186  + + + x x.x x.x, x.x  x x.x x.x, x.x  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 60 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 38: Percentage of Influenza -Specific CD4+ Cell Subsets Expressing Discrete Memory 
Markers ( CCR7, CD45RO, and CD57 ) by Study Arm  and Study Day, Per Protocol 
Population (Continued)  
Study Day  CCR7  CD45RO  CD57  Group A: 1 mg M -001 Group B: Placebo  
n GMP  95% CI  n GMP  95% CI 
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x.x  x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x 
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x .x x.x, x.x  x x.x x.x, x.x  
Day 200  + + + x x.x x.x, x.x  x x.x x.x, x.x  
 + + - x x.x x.x, x.x  x x.x x.x, x.x  
 + - - x x.x x.x, x.x  x x.x x.x, x.x  
 + - + x x.x x.x, x.x  x x.x x.x, x.x  
 - + + x x.x x.x, x.x  x x.x x.x, x.x  
 - + - x x.x x.x, x.x  x x.x x.x, x.x  
 - - + x x.x x.x, x.x  x x.x x.x, x.x  
 - - - x x.x x.x, x.x  x x.x x.x, x.x  
 + +/- +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- + +/- x x.x x.x, x.x  x x.x x.x, x.x  
 +/- +/- + x x.x x.x, x.x  x x.x x.x, x.x  
Note: N  = number of subjects in Per Protocol po pulation.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 61 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Tables with similar format: 
Table 39: Percentage of Influenza -Specific CD 8+ Cell Subsets Expressing Discrete Memory 
Markers ( CCR7, CD45RO, and CD57 ) by Study Arm and Study Day, Per Protocol 
Population 
Table 40: Percentage of Influenza -Specific CD4+ Cell Subsets express ing IL-4 or IL-17 by Study 
Arm  and Study Day, Per Protocol  Population 
Table 41: Percentage of Influenza -Specific C D4+ Cell Subsets expressing T Follicular Helper Cells 
(CD4+, CXCR5+, PD-1+, IL-21+) by Study Arm  and St udy Day, Per Protocol  Population 
Table 42: Percentage of Influenza -Specific CD4+ Cell Subsets expressing T Follicu lar Regulatory 
Cells (CXCR5+, PD-1+, CD25+, CD127+) by Study Arm  and Study Day, Per Protocol  
Population 
Table 43: Percentage of Influenza -Specific CD4+ Cell Subsets expressing Tregs (CD25+, Foxp3+) 
by Study Arm  and St udy Day, Per Protocol  Population 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 62 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 44: Summaries of ELISA Antibody Against M -001 by Study Day  and Study Arm , Per 
Protocol  Population  
Study Day  Group A : 1 m g M-001 Group B: Placebo  
N GMT (95% CI)  Seroconversio n  
% (95% CI)  N GMT (95% 
CI) Seroconversion  
% (95% CI)  
Baseline x x.x (x.x, x.x)  NA x x.x (x.x, x.x)  NA 
Day 22  x x.x (x.x, x.x)  xx (xx, xx)  x x.x (x.x, x.x)  xx (xx, xx)  
Day 43  x x.x (x.x, x.x)  xx (xx, xx)  x x.x (x.x, x.x)  xx (xx, xx)  
Day 78  x x.x (x.x, x.x)  xx (xx, xx)  x x.x (x.x, x.x)  xx (xx, xx)  
Day 172  x x.x (x.x, x.x)  xx (xx, xx)  x x.x (x.x, x.x)  xx (xx, xx)  
Day 200  x x.x (x.x, x.x)  xx (xx, xx)  x x.x (x.x, x.x)  xx (xx, xx)  
Note s: N=Number of subject s in Per Protocol  population . 
Seroconversion is  defined as either  a pre-vaccination titer <10 and a post -vaccination titer ‚â• 40 or a pre-vaccination titer ‚â• 10 and a minimum 
four-fold rise in post -vaccination antibody titer.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 63 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3 Safety Data 
14.3.1 Displays of Adverse Events Table 45: Overall Summary of Adverse Events * 
 Group A : 
1 mg M -001 
(N = xx)  Group B : 
Placebo  
(N = xx)  All Subjects  
(N = xx)  
Subjectsa with n % n % n % 
       
At least one local solicited adverse event  x x x x x x 
     Mild (Grade 1)  x x x x x x 
     Moder ate (Grade 2)  x x x x x x 
     Severe (Grade 3)  x x x x x x 
At least one systemic solicited adverse event  x x x x x x 
     Mild (Grade 1)  x x x x x x 
     Moderate (Grade 2)  x x x x x x 
     Severe (Grade 3)  x x x x x x 
       
At least one unsolicited adverse event  x x x x x x 
       
At least one related unsolicited adverse event  x x x x x x 
     Mild (Grade 1)  x x x x x x 
     Moderate (Grade 2)  x x x x x x 
     Severe (Grade 3)  x x x x x x 
     Not yet assessed        
       
At least one severe (Grade 3) unsolicited adverse event  x x x x x x 
     Related  x x x x x x 
     Unrelated  x x x x x x 
       
At least one unsolicited non-serious Adverse Event  from first study vaccination 
through 21 days after each M -001 vaccination  x x x x x x 
At least one serious adverse eventb x x x x x x 
At least one related, serious adverse event  x x x x x x 
At least one adverse event leading to early terminationc  x x x x x x 
       
At least one clinical safety laboratory adverse event  x x x x x x 
     Mild (Grade 1)  x x x x x x 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 64 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION   Group A : 
1 mg M -001 
(N = xx)  Group B : 
Placebo  
(N = xx)  All Subjects  
(N = xx)  
Subjectsa with n % n % n % 
     Moderate (Grade 2)  x x x x x x 
     Severe (Grade 3)  x x x x x x 
     Not yet assessed        
Note s: N=Number of subjects in Safety Analysis population.  
a Subjects are counted once for each category regardless of the n umber of events.  
b A listing of Serious Adverse Events is included in Table 58.  
c As reported on the Adverse Event eCRF.  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 65 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 46: Adverse Events Occurring in 5% of Subjects in Any Study Arm  by MedDRA System Organ C lass and Preferred Term, and 
Study Arm  
MedDRA System Organ Class  Preferred Term  Group A : 1 mg M -001 
(N=X ) Group B: Placebo  
(N=X ) All Subjects  
(N=X ) 
  n % Events  n % Events  n % Events  
Serious Adverse Events  
All  All x x x x x x x x x 
SOC1  PT1 x x x x x x x x x 
Etc. Etc.          
Other (Non -serious) Adverse Events  
All  All x x x x x x x x x 
SOC1  PT1 x x x x x x x x x 
Etc Etc          
Note s: N=N umber of subjects in  Safety  Analysis  population  
n= number of subjects reporting event. Events= total freque ncy of events reported.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 66 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.1.1 Solicited Adverse Events  
Table 47: Number and Percentage of Subjects Experiencing Solicited Events with 95% Confidence Intervals by Symptom,  Dose, and Study 
Arm* 
Symptom  Post Dose 1  
Group A: 1 mg M -001 
(N=X)  Post Dose 1  
Group B: Placebo  
(N=X)  Post Do se 2 
Group A: 1 mg M -001 
(N=X)  Post Dose 2  
Group B: Placebo  
(N=X)  Post Any Dose  
Group A: 1 mg M -001 
(N=X)  Post Any Dose  
Group B: Placebo  
(N=X)  
n % 95% CI  n % 95% CI  n % 95% CI  n % 95% C I n % 95% CI  n % 95% CI  
Any Symptom  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  
Any Systemic Symptom                    
Fever                    
Feverishness                    
Fatigue                    
Malaise                   
Myalgia                    
Arthralgia                    
Headache                    
Nausea                    
Any Local Symptom                    
Pain                   
Tenderness                    
Ecchymosis                    
Ecchym osis (measurement)                    
Erythema                    
Erythema (measurement)                    
Induration/Swelling                    
Induration/Swelling 
(measurement)                    
Note: N=Number of subjects in Safety Analysis p opulation . 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 67 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 48: Comparison of the Proportion of Subjects Experiencing Solicited Events by Study Arm  
Symptom  Statistic Group A: 1 mg M -001 
Post Either Dose  
(N=X)  Group B: Placebo  
Post Either Dose  
(N=X)  
Any Symptom  Prop ortion  x.xx x.xx 
 95% CI (for proportion)  x.xx, x.xx  x.xx, x.xx  
 Difference   x.xx 
 95% CI (for difference)   x.xx, x.xx  
[Symptom 1]  Proportion    
 95% CI (for proportion)    
 Difference    
 95% CI (for difference)    
[Repeat for all solicited events]  
Note: N =Number of subjects in Safety  Analysis  population . 
  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 68 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 49: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and  Study Arm * 
Symptom  Severity  Post Dose 1  
Group A : 1 mg M -001 
(N=X)  Post Dose 1  
Group B: Placebo  
(N=X)  Post Dose 2 
Group A: 1 mg M -001 
(N=X)  Post Dose 2  
Group B: Placebo  
(N=X)  Post Any Dose  
Group A: 1 mg M -001 
(N=X)  Post Any Dose  
Group B: Placebo  
(N=X)  
n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  
Any Symptom  None  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  
 Mild                    
 Moderate                    
 Severe                    
Systemic Symptoms  
Any Systemic 
Symptom  None  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  x xx x.x, x.x  
 Mild                    
 Moderate                    
 Severe                    
Fever  None                    
 Mild                    
 Moderate                    
 Severe                    
Feverishness  None                    
 Mild                    
 Moderate                    
 Severe                    
Fatigue  None                    
 Mild                    
 Moderate                    
 Severe                    
Malaise None                   
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 69 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 49: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Study Arm* 
(Continued)  
Symptom  Severity  Post Dose 1  
Group A: 1 mg M -001 
(N=X)  Post Dose 1  
Grou p B: Placebo  
(N=X)  Post Dose 2  
Group A: 1 mg M -001 
(N=X)  Post Dose 2  
Group B: Placebo  
(N=X)  Post Any Dose  
Group A: 1 mg M -001 
(N=X)  Post Any Dose  
Group B: Placebo  
(N=X)  
n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  
 Mild                    
 Moderate                    
 Severe                    
Myalgia  None                    
 Mild                    
 Moderate                    
 Severe                    
Arthralgia  None                    
 Mild                    
 Moderate                    
 Severe                    
Headache  None                    
 Mild                    
 Moderate                    
 Severe                    
Nausea  None                    
 Mild                    
 Moderate                    
 Severe                    
Local Symptoms  
Any Local Symptom  None  x xx  x xx  x xx  x xx  x xx  x xx  
 Mild                    
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 70 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 49: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Study Arm * 
(Continued)  
Symptom  Severity  Post Dose 1  
Group A: 1 mg M -001 
(N=X)  Post Dose 1  
Group B: Placebo  
(N=X)  Post Dose 2  
Group A: 1 mg M -001 
(N=X)  Post Dose 2  
Group B: Placebo  
(N=X)  Post Any Dose  
Group A: 1 mg M -001 
(N=X)  Post Any Dose  
Group B: Placebo  
(N=X)  
n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  
 Moderate                    
 Severe                    
Pain None                    
 Mild                    
 Moderate                    
 Severe                    
Tenderness  None                    
 Mild                    
 Moderate                    
 Severe                    
Pruritus  None                    
 Mild                    
 Moderate                    
 Severe                    
Ecchymosis  None                    
 Mild                    
 Moderate                    
 Severe                    
Ecchymosis (measurement)  None                    
 Mild                    
 Moderate                    
 Severe                    
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 71 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 49: Number and Percentage o f Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Study Arm* 
(Continued)  
Symptom  Severity  Post Dose 1  
Group A: 1 mg M -001 
(N=X)  Post Dose 1  
Group B: Placebo  
(N=X)  Post Dose 2  
Group A: 1 mg M -001 
(N=X)  Post Dose 2  
Group B: Pla cebo  
(N=X)  Post Any Dose  
Group A: 1 mg M -001 
(N=X)  Post Any Dose  
Group B: Placebo  
(N=X)  
n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  n % 95% CI  
Erythema  None                    
 Mild                    
 Moderate                    
 Severe                    
Erythema (measurement)  None                    
 Mild                    
 Moderate                    
 Severe                    
Induration/Swelling  None                    
 Mild                    
 Moderate                    
 Severe                    
Induration/Swelling 
(measurement)  None                    
 Mild                    
 Moderate                    
 Severe                    
Note s: N=Number of subjects in Safety Analysis population who received the specified dose.  
Severity is t he maximum severity reported over all solicited symptoms post dosing for each subject.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 72 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 50: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Severity,  and Day Post Dosing, Group A: 1  mg 
M-001, Post First Vaccination  
Group A: 1 mg M -001, Post Dose 1 (N=X)  
Symptom  Severity  Pre-Dose  Post-Dose  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
n % n % n % n % n % n % n % n % n % n % 
Any Symptom  None  x xx x xx x xx x xx x xx x xx x xx x xx x xx x xx 
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Systemic Symptoms   
Any Systemic  
Symptom  None  x xx x xx x xx x xx x xx x xx x xx x xx x xx x xx 
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Fever  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Feverishness  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 73 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 50: Number and Percentage of Subjects Experiencing Solicited Events  by Symptom, Severity, and Day Post Dosing, Group A: 1 mg 
M-001, Post First Vaccination (Continued) 
Group A: 1 mg M -001, Post Dose 1 (N=X)  
Symptom  Severity  Pre-Dose  Post-Dose  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
n % n % n % n % n % n % n % n % n % n % 
Fatigue  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Malaise None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Arthralgia  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Headache  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Nausea  None                      
 Mild                      
 Moderate                      
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 74 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 50: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Severity,  and Day Post Dosing, Group A: 1 mg 
M-001, Post First Vaccination (Continued) 
Group A: 1 mg M -001, Post Dose 1 (N=X)  
Symptom  Severity  Pre-Dose  Post-Dose  Day 1 Day 2 Day 3 D ay 4 Day 5 Day 6 Day 7 Day 8 
n % n % n % n % n % n % n % n % n % n % 
 Severe                      
 Not Reported                      
Local Symptoms   
Any Local Symptom  None  x xx x xx x xx x xx x xx x xx x xx x xx x xx x xx 
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Pain None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Tendernes s None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Pruritis  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 75 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 50: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Severity,  and Day Post Dosing, Group A: 1 mg 
M-001, Post First Vaccination (Continued) 
Group A : 1 mg M -001, Post Dose 1 (N=X)  
Symptom  Severity  Pre-Dose  Post-Dose  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
n % n % n % n % n % n % n % n % n % n % 
Ecchymosis  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Ecchymosis (measurement)  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Erythema  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Erythema (measurement)  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Induration/Swelling  None                      
 Mild                      
 Moderate                      
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 76 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 50: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Severity, and Day Post Dosing, Group A: 1 mg 
M-001, Post First Vaccination (Continued) 
Group A: 1 mg M -001, Post Dose 1 (N=X)  
Symptom  Severity  Pre-Dose  Post-Dose  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
n % n % n % n % n % n % n % n % n % n % 
 Severe                      
 Not Reported                      
Induration/Swelling 
(measurement)  None                      
 Mild                      
 Moderate                      
 Severe                      
 Not Reported                      
Note s: N=Number of subjects in Safety Analysis  population who received the specified dose.  
Severity is the maximum severity reported post dosing for each subject for each day.  
 
Tables with similar format: 
Table 51: Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Severity,  and Day Post Dosing, Group A: 1 mg 
M-001, Post Second Vaccination 
Table 52: Number and Per centage of Subjects Experiencing Solicited Events by Symptom, Severity, and Day Post Dosing, Group B: 
Placebo, Post First Vaccination 
Table 53: Number and Percentage of Subjects Experiencing Solicited Events by Sympto m, Severity, and Day Post Dosing, Group B : 
Placebo, Post Second Vaccination 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 77 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 54: Number and Percentage of Subjects Experiencing Solicited Events for Dose 1 Compared with Dose 2 by Study A rm 
Study Arm   Dose 2 ‚Äì Subjects with 
No Symptoms  Dose 2 ‚Äì Subjec ts with 
Mild or Greater Symptoms  Dose 2 ‚Äì Total 
Number of Subjects  McNemar‚Äôs  Test Result 
(p-value)  
Systemic Symptoms   
Group A: 1 mg M -001 Dose 1 Subject with No Symptoms  x (%)  x (%)  x (%)   
 Dose 1 Subjects with Mild or Greater Symptoms  x (%)  x (%)  x (%)  
 Dose 1 Total Number of Subjects  x (%)  x (%)  x (100%)   
Group B: Placebo  Subject with No Symptoms      
 Subjects with Mild or Greater Symptoms      
 Total Number of Subjects      
Local Symptoms   
Group A: 1 mg M -001 Dose 1 Subjects with No Symptom s  x (%)  x (%)  x (%)   
 Dose 1 Subjects with Mild or Greater Symptoms  x (%)  x (%)  x (%)   
 Dose 1Total Number of Subjects  x (%)  x (%)  x (100%)   
Group B: Placebo  Dose 1 Subjects with No Symptoms      
 Dose 1Subjects with Mild or Greater Symptoms      
 Dose Total Number of Subjects      
Note s: N=N umber of subjects in Safety Analysis population who received the first and second dose.  
[x] subjects did not get the second dose and are not included in this table.  
 
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 78 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.1.2 Unsolicited Adverse Events  
Table 55: Summary of Unsolicited Adverse Events by  MedDRA System Organ Class and Preferred Term, Dose Number, and Study A rm 
MedDRA System 
Organ Class  MedDRA Preferred 
Term  Day 1-8 
Post Dose 1  
(N=X)  Day 9 -22 
Post Dose 1  
(N=X)  Day 1 -8 
Post Dose 2  
(N=X)  Day 9 -22 
Post Dose 2  
(N=X)  Any Time Post Any Dose  
(N=X)  
n % 95% 
CI Events  n % 95% 
CI Events n % 95% 
CI Events n % 95% 
CI Events  n % 95% 
CI Events 
Group A: 1 mg M -001 
Any SOC  Any PT  x xx xx, xx  x x xx xx, xx  x x xx xx, xx  x x xx xx, xx  x x xx xx, xx  x 
[SOC 1]  Any PT                      
 [PT 1]                      
 [PT 2]                      
[SOC 2]  Any PT                      
 [PT 1]                      
 [PT 2]                      
Group B: Placebo  
Any SOC  Any PT  x xx xx, xx  x x xx xx, xx  x x xx xx, xx  x x xx xx, xx  x x xx xx, xx  x 
[SOC 1]  Any PT                      
 [PT 1]                      
 [PT 2]                      
[SOC 2]  Any PT                      
 [PT 1]                      
 [PT 2]                      
Note s: N=Number of subjects in Safety Analysis  population who received the specified dose.  
This table presents number and percentage of subjects.  
A subject is only counted once per PT/time point.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 79 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 56: Unsolicited Adverse Events by MedDRA  System Organ Class and Preferred Term, Maximum Severity, Relationship, and Study 
Arm* 
MedDRA System Organ Class  Preferred Term  Severity  Group A: 1 mg M -001 
(N = X)  Group B: Placebo  
(N = X)  
Related  Not Related  Total  Related  Not Related  Total  
n % n % n % n % n % n % 
Any SOC  Any PT  Any Severity  x  xx x  xx x  xx x  xx x  xx x  xx 
  Mild  x  xx x  xx x  xx x  xx x  xx x  xx 
  Moderate  x  xx x  xx x  xx x  xx x  xx x  xx 
  Severe  x  xx x  xx x  xx x  xx x  xx x  xx 
SOC 1  PT 1  Any Severity  x  xx x  xx x  xx x  xx x  xx x  xx 
  Mild  x  xx x  xx x  xx x  xx x  xx x  xx 
  Moderate  x  xx x  xx x  xx x  xx x  xx x  xx 
  Severe  x  xx x  xx x  xx x  xx x  xx x  xx 
 PT 2  Any Severity  x  xx x  xx x  xx x  xx x  xx x  xx 
  Mild  x  xx x  xx x  xx x  xx x  xx x  xx 
  Moderate  x  xx x  xx x  xx x  xx x  xx x  xx 
  Severe  x  xx x  xx x  xx x  xx x  xx x  xx 
Note: N=Number of subjects in Safety Analysis population.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 80 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 57: Related Unso licited Adverse Events Within 21  Days Post Dosing by MedDRA System Organ Class and Preferred Term, Dose, 
and Study Arm 
 
 Day 1-22 
Post Dose 1  Day 1 -22 
Post Dose 2  Within 21  Days Post Either Dose  
MedDRA System Organ Class  MedDRA Preferred Term  n % Events n % Events n % Events 
Group A: 1 mg M -001 
Any SOC  Any PT  x xx x x xx x x xx x 
[SOC 1]  Any PT           
 [PT 1]           
 [PT 2]           
[SOC 2]  Any PT           
 [PT 1]           
 [PT 2]           
Group B: Placebo  
Any SOC  Any PT           
[SOC 1]  Any PT           
 [PT 1]           
 [PT 2]           
[SOC 2]  Any PT           
 [PT 1]           
 [PT 2]           
Note s: N=Number of subjects in  Safety Analysis population . 
This table presents number and percentage of subjects.  
For each time point, a subject is only counted once per PT.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 81 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.2 Listing of Deaths, Other Serious and Significant Adverse Events  
Table 58: Listing of Serious Adverse Events * 
Adverse 
Event  Associated 
with Dose 
No. No. of Days 
Post Associated 
Dose 
(Duration)  No. of Days 
Post Dose the 
Event Became 
Serious  Reason 
Reported as 
an SAE  Severity  Relationship 
to Study 
Treatment  If Not 
Related, 
Alternative 
Etiology  Action 
Taken with 
Study 
Treatment  Subject 
Discontinued 
Due to AE  Outcome  MedDRA 
System 
Organ 
Class MedDRA 
Preferred 
Term  
Subject ID: , Study Arm : , AE Number:   
             
Comments : 
 
Subject ID: , Study Arm : , AE Number:   
             
Comments : 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 82 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.3 Narratives of Deaths, Other Serious  and Significant Adverse Events  
(not included in SAP, but this is a placeholder for the CSR)  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 83 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.4 Abnormal Laboratory Value L isting s (by Subject)  
Table 59: Listing of Abnormal Laboratory Results - Chemistry  
Subject  
ID Study Arm  Sex Age 
(years)  Planned 
Study Day  Actual 
Study Day  Laboratory 
Parameter  
(Units)  Result 
(Severity)  Relationship to 
Treatment  If Not Related, 
Alternate 
Etiology  Action Taken 
with Study 
Treatment  Subject 
Discontinued Due 
to Result?  
            
            
            
            
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 84 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 60: Listing of Abnormal Laboratory Results - Hematology 
Subject  
ID Study Arm  Sex Age 
(years)  Planned 
Study Day  Actual 
Study Day  Laboratory 
Parameter  
(Units)  Result 
(Severity)  Relationship to 
Treatment  If Not Related, 
Alternate 
Etiology  Action Taken 
with Study 
Treatment  Subject 
Discontinued Due 
to Result?  
            
            
            
            
            
            
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 85 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.5 Displays of Laboratory Results 
14.3.5.1 Chemistry Results  
Table 61: Laboratory Results by Parameter, Maximum Severity, Study Day , and Study Arm ‚Äì Any Chemistry Parameter  
Study Day  Study Arm  N None  Mild /  
Grade 1  Moderate/  
Grade 2  Severe/  
Grade 3  Missing  
n % n % n % n % n % 
Baseline Group A: 1 mg M -001 x x xx x xx x xx x xx x xx 
 Group B: Placebo             
Day 9  Group A: 1 mg M -001            
 Group B: Placebo             
Day 30  Group A: 1 mg M-001             
 Group B: Placebo             
Max Severity Post Baseline  Group A: 1 mg M -001            
 Group B: Placebo             
Note s: N=number of subjects in Safety Analysis population.  
The ‚ÄúMax Post Baseline‚Äù rows indicate the maximum severity experienced by each subject at any time point post baseline, inclu ding unscheduled assessments.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 86 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 62: Laboratory Results by Parameter, Study Day , and Study A rm ‚Äì Alanine Aminotransferase  
Study Day  Study Arm  N None  Mild/  
Grade 1  
(Low) Mild/  
Grade 1  
(High)  Moderate/  
Grade 2  
(Low) Moderate/  
Grade 2  
(High)  Severe/  
Grade 3 
(Low) Severe/  
Grade 3  
(High)  Missing  
n % n % n % n % n % n % n % n % 
Baseline Group A: 1 mg M -001 x x xx x xx x xx x xx x xx x xx x xx x xx 
 Group B: Placebo                   
Day 9  Group A: 1 mg M -001                  
 Group B: Placebo                   
Day 30  Group A: 1 mg M -001                  
 Group B: Placebo                   
Max Severity Post 
Baseline Group A: 1 mg M -001                  
 Group B: Placebo                   
Note s: N=number of s ubjects in Safety Analysis population . 
The ‚ÄúMax Post Baseline‚Äù rows indicate the maximum severity experienced by each subject at any time point post baseline, inclu ding unscheduled assessments.  
 
Tables wit h similar format: 
Table 63: Laboratory Results by Parameter, Study Day , and Study Arm ‚Äì Total Bilirubin  
Table 64: Laboratory Results by Parameter, Study Day , and Study A rm ‚Äì Creatinine  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 87 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 65: Laboratory Summary Statistics by Parameter, Study Day , and Study A rm ‚Äì Alanine Aminotransferase*  
Study Day  Study Arm  N Mean  Standard Deviation  Median  Min, Max  
Baseline Group A: 1 mg M -001 x xx.x xx.x xx.x xx.x, xx.x  
 Group B: Placebo       
Day 9  Group A: 1 mg M -001      
 Group B: Placebo       
Day 30  Group A: 1 mg M-001       
 Group B: Placebo       
Max Severity Post Baseline  Group A: 1 mg M -001      
 Group B: Placebo       
Note: N =number of subjects in Safety Analysis p opulation.  
 
Tables with similar format: Table 66: Laboratory Summary Statistics by Parameter, Study Day , and Study A rm ‚Äì Total Bilirubin * 
Table 67: Laboratory Summary Statistics by Parameter, Study Day , and Study A rm ‚Äì Creatin ine*  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 88 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.5.2 Hematology Results  
Table 68: Laboratory Results by Parameter, Maximum Severity, Study Day , and Study A rm ‚Äì Any Hematology Parameter 
Study Day  Study Arm  N None  Mild /  
Grade 1  Moderate/  
Grade 2  Severe/  
Grad e 3 Missing  
n % n % n % n % n % 
Baseline Group A: 1 mg M -001 x x xx x xx x xx x xx x xx 
 Group B: Placebo             
Day 9  Group A: 1 mg M -001            
 Group B: Placebo             
Day 30  Group A: 1 mg M -001            
 Group B: Placebo             
Max Severity Post Baseline  Group A: 1 mg M -001            
 Group B: Placebo             
Note s: N=number of subjects in Safety Analysis population.  
The ‚ÄúMax Post Baseline‚Äù rows indicate the maximum severity experienced by each subject at any time poin t post baseline, inc luding unscheduled assessments.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 89 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 69: Laboratory Results by Parameter, Maximum Severity, Study Day , and Study A rm ‚Äì White Blood Cells  
Study Day  Study Arm  N None  Mild/  
Grade 1  
(Low) Mild/  
Grade 1  
(High)  Moderate/  
Grade 2  
(Low) Moderate/  
Grade 2  
(High)  Severe/  
Grade 3  
(Low) Severe/  
Grade 3  
(High)  Missing  
n % n % n % n % n % n % n % n % 
Baseline Group A: 1 mg M -001 x x xx x xx x xx x xx x xx x xx x xx x xx 
 Group B: Placebo                   
Day 9  Group A: 1 mg M -001                  
 Group B: Placebo                   
Day 30  Group A: 1 mg M -001                  
 Group B: Placebo                   
Max Severity Post 
Baseline Group A: 1 mg M -001                  
 Group B: Placebo                   
Note s: N=number of subjects in Safety Analysis population.  
The ‚ÄúMax Post Baseline‚Äù rows indicate the maximum severity experienced by each subject at any time point post baseline, inc luding unscheduled assessments.  
 
Tables with similar format: 
Table 70: Laboratory Results by Parameter, Maximum Severity, Study Day , and Study A rm ‚Äì Hemoglobin  
Table 71: Laboratory Results by Parameter, Maximum Severi ty, Study Day , and Stu dy A rm ‚Äì Platelets  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 90 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 72: Laboratory Summary Statistics by Parameter, Study Day , and Study  Arm ‚Äì White Blood Cells* 
Study Day  Study Arm  N Mean  Standard Deviation  Median  Min, Max  
Baseline Group A: 1 mg M -001 x xx.x xx.x xx.x xx.x, xx.x  
 Group B: Placebo  x xx.x xx.x xx.x xx.x, xx.x  
Day 9  Group A: 1 mg M -001 x xx.x xx.x xx.x xx.x, xx.x  
 Group B: Placebo  x xx.x xx.x xx.x xx.x, xx.x  
Day 30  Group A: 1 mg M -001 x xx.x xx.x xx.x xx.x, xx.x  
 Group B: Placebo  x xx.x xx.x xx.x xx.x, xx.x  
Max Severity Post Baseline  Group A: 1 mg M -001 x xx.x xx.x xx.x xx.x, xx.x  
 Group B: Placebo  x xx.x xx.x xx.x xx.x, xx.x  
Note: N= number of subjects in Safety Analysis p opulation.  
 
Tables with similar format: 
Table 73: Laboratory Summary Statistics by Parameter, Study Day , and Study A rm ‚Äì Hemoglobin* 
Table 74: Laboratory Summary Statistics by Parameter, Study Day , and Study A rm ‚Äì Platelets * 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 91 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.6 Displays of Vital Signs 
Table 75: Vital Signs by Assessment, Maximum Severity, Study Day , and Study A rm ‚Äì Any Assessment  
Study Day  Study Arm  N None  Mild  Moderate  Severe  Missing  
n % n % n % n % n % 
Baseline Group A: 1 mg M -001 x x xx x xx x xx x xx x xx 
 Group B: Placebo  x x xx x xx x xx x xx x xx 
Day 22  Group A: 1 mg M -001 x x xx x xx x xx x xx x xx 
 Group B: Placebo  x x xx x xx x xx x xx x xx 
Day 172  Group A: 1 mg M -001 x x xx x xx x xx x xx x xx 
 Group B: P lacebo  x x xx x xx x xx x xx x xx 
Max Severity Post Baseline  Group A: 1 mg M -001 x x xx x xx x xx x xx x xx 
 Group B: Placebo  x x xx x xx x xx x xx x xx 
Note s: N=number of subjects in Safety Analysis population.  
The ‚ÄúMax Post Baseline‚Äù rows indicate the  maximum severity experienced by each subject at any time point post baseline, including unscheduled assessme nts.  
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 92 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Table 76: Vital Signs by Assessment, Maximum Severity, Study Day , and Study Arm ‚Äì Systolic Blood P ressure  
Study Day  Study Arm  N None  Mild  
(Low) Mild  
(High)  Moderate  
(Low) Moderate  
(High)  Severe  
(Low) Severe  
(High)  Missing  
n % n % n % n % n % n % n % n % 
Baseline Group A: 1 mg M -
001 x x xx x xx x xx x xx x xx x xx x xx x xx 
 Group B: Placebo  x x xx x xx x xx x xx x xx x xx x xx x xx 
Day 22  Group A: 1 mg M -
001 x x xx x xx x xx x xx x xx x xx x xx x xx 
 Group B: Placebo  x x xx x xx x xx x xx x xx x xx x xx x xx 
Day 172   Group A: 1 mg M -
001 x x xx x xx x xx x xx x xx x xx x xx x xx 
 Group B: Place bo x x xx x xx x xx x xx x xx x xx x xx x xx 
Max Severity Post 
Baseline Group A: 1 mg M -
001 x x xx x xx x xx x xx x xx x xx x xx x xx 
 Group B: Placebo  x x xx x xx x xx x xx x xx x xx x xx x xx 
Note s: N=number of subjects in Safety Analysis population.  
The ‚ÄúMax Post Baseline‚Äù rows indicate the maximum severity experienced by each subject at any time point post baseline, inclu ding unscheduled assessments.  
 
Tables with similar format: 
Table 77: Vital Signs by Assessment, Maximum Severity, Study Day , and Study A rm ‚Äì Diastolic Blood Pressure 
Table 78: Vital Signs by Assessment, Maximum Severity, Study Day , and Study A rm ‚Äì Oral Temperature  
Table 79: Vital Signs by Assessment, Maximum Severity, Study Day , and Study A rm ‚Äì Pulse  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 93 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.4 Summary of Concomitant Medications 
Table 80: Number and Percentage of Subjects with Prior and Concurrent Medications by WHO 
Drug Classification and Study A rm 
WHO Drug Code  
Level 1, Anatomic Group  WHO Drug Code  
Level 2, Therapeutic Subgroup  Group A : 1 mg M -001 
(N=X)  Group B: Placebo  
(N=X)  All Subjects  
(N=X)  
n % n % n % 
Any Level 1 Codes  Any Level 2 Codes  x xx x xx x xx 
[ATC  Level 1 - 1] Any [ATC 1 ‚Äì 1] x xx x xx x xx 
 [ATC 2 - 1] x xx x xx x xx 
 [ATC 2 - 2] x xx x xx x xx 
 [ATC 2 - 3] x xx x xx x xx 
[ATC Level 1 ‚Äì 2] [ATC 2 - 1] x xx x xx x xx 
 [ATC 2 - 2] x xx x xx x xx 
 [ATC 2 - 3] x xx x xx x xx 
Note s: N=number of subjects in Safety Analysis p opulation.  
n=Number of subjects reporting taking at least one medication in the specific WHO Drug Class.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 94 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  APPENDIX 2.  FIGURE MOCK -UPS  
LIST OF FIGURES  
Figure  1: CONSORT Flow Diagram  .........................................................................................98  
Figure  2: Box Plots of Percentage of Selected CD4+ T Cell Subsets Expressing 
Markers After M -001 Stimulation by Study Arm and Study Day, Per 
Protocol Population* ..................................................................................................99  
Figure  3: Box Plots of Percentage of Selected CD4+ T Cell Subsets Expressing Markers After M -001 Stimulation by Study Arm and Study Day, Modified 
Intent- to-Treat Population* ......................................................................................100
 
Figure  4: Box Plots of Percentage of Selected CD8+ T Cell Subsets Expressing Markers After M -001 Stimulation by Study Arm and Study Day, Per 
Protocol Population* ................................................................................................100
 
Figure  5: Box Plots of Percentage of Selected CD8+ T Cell Subsets Expressing Markers After M -001 Stimulation by Study Arm and Study Day, Modified 
Intent- to-Treat Population* ......................................................................................100
 
Figure  6: Box Plots of Percentage of Selected CD4+ T Cell Subsets Expressing Markers After Seasonal Influenza A Antigen Stimulation by Study Arm and 
Study Day, Per Protocol Population .........................................................................100
 
Figure  7: Box Plots of Percentage of Selected CD4+ T Cell Subsets Expressing 
Markers After Pandemic Influenza A Antigen Stimulation by Study Arm and Study Day, Per Protocol Population .........................................................................100
 
Figure  8: Box Plots of Percentage of Selected CD8+ T Cell Subsets Expressing 
Markers After Seasonal Influenza A Antigen Stimulation by Study Arm and 
Study Day, Per Protocol Population .........................................................................100  
Figure  9: Box Plots of Percentage of Selected CD8+ T Cell Subsets Expressing 
Mark ers After Pandemic Influenza A Antigen Stimulation by Study Arm and 
Study Day, Per Protocol Population .........................................................................100  
Figure  10: Reverse Cumulat ive Distribution of Hemagglutination Inhibition Antibody 
Against A/Michigan/45/2015 X-275 (H1N1) by Study Day and Study Arm, 
Per Protocol Population ............................................................................................101  
Figure  11: Reverse Cumulative Distribution of Hemagglutination Inhibition Antibody 
Against A/Singapore/INFIMH-16-0019/2016 NIB-104 (H3N2)- Guinea RBC 
by Study Day and Study Arm, Per Protocol Population ...........................................102  
Figure  12: Reverse Cumulative Distribution of Hemagglutination Inhibition Antibody Against B/Colorado/6/2017 (B Victoria Lineage) by Study Day and Study 
Arm, Per Protocol Population ...................................................................................102
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 95 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  13: Reverse Cumulative Distribution of Hemagglutination Inhibition Antibody 
Against B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day and 
Study Arm, Per Protocol Population ........................................................................102  
Figure  14: Reverse Cumulative Distribution of Neut ralizing Antibody Against 
A/Michigan/45/2015 X-275 (H1N1) by Study Day and Study Arm, Per Protocol Population ..................................................................................................102
 
Figure  15: Reverse C umulative Distribution of Neutralizing Antibody Against 
A/Singapore/INFIMH-16-0019/2016 NIB-104(H3N2) by Study Day and Study Arm, Per Protocol Population ........................................................................102
 
Figure  16: Reverse Cumulative Distribution of Neutralizing Antibody Against 
B/Colorado/6/2017 (B Victoria Lineage) by Study Day and Study Arm, Per 
Protocol Population ..................................................................................................102  
Figure  17: Reverse Cumulative Distribution of Neutralizing Antibody Against 
B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day and Study Arm, 
Per Protocol Population ............................................................................................102  
Figure  18: Correlation of Hemagglutination Inhibition Antibody and Neutralizing 
Antibody Against A/H1N1 by Study Day and Study Arm, Per Protocol 
Population .................................................................................................................103  
Figure  19: Correlation of Hemagglutination Inhibition Antibody and M-001 Antibody 
Against A/ H1N1 by Study Day and Study Arm, Per Protocol Population ..............104  
Figure  20: Correlation of Neutralizing Antibody and M-001 Antibody Against A/H1N1 
by Study Day and Study Arm, Per Protocol Population ...........................................104  
Figur e 21:  Correlation of Hemagglutination Inhibition Antibody and Neutralizing Antibody against A/H3N2 by Study Day and Study Arm, Per Protocol Population .................................................................................................................104
 
Figure  22: Correlation of Hemagglutination Inhibition Antibody and M-001 Antibody Against A/H3N2 by Study Day and Study Arm, Per Protocol Population ..............104
 
Figure  23: Correlation of Neutralizing Antibody and M-001 Antibody Against A/H3N2 
by Study Day and Study Arm, Per Protocol Population ...........................................104  
Figure  24: Correlation of Hemagglutination Inhibition Antibody and Neutralizing 
Antibody Against B/Colorado/6/2017 (B Victoria Lineage) by Study Day 
and Study Arm, Per Protocol Population ..................................................................104  
Figure  25: Correlation of Hemagglutination Inhibition Antibody and M-001 Antibody 
Against B/Colorado/6/2017 (B Victoria Lineage) by Study Day and Study 
Arm, Per Protocol Population ...................................................................................104  
Figure  26: Correlation of Neutralizing Antibody and M-001 Antibody Against 
B/Colorado/6/2017 (B Victoria Lineage) by Study Day and S tudy Arm, Per 
Protocol Population ..................................................................................................104  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 96 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  27: Correlation of Hemagglutination Inhibition Antibody and Neutralizing 
Antibody Against B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day 
and Study Arm, Per Protocol Population ..................................................................104  
Figure  28: Correlation of Hemagglutination Inhibition Antibody and M-001 Antibody 
Against B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day and 
Study Arm, Per Protocol Population ........................................................................104  
Figure  29: Correlation of Neutralizing Antibody and M-001 Antibody Against 
B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day and Study Arm, 
Per Protocol Population ............................................................................................104  
Figure  30: Box Plots of Percentage of Influenza- Specific CD4+ T Cell Subsets 
Expressing Discrete Memory Markers (CCR7, CD45RO, CD57) by Study Arm and Study Day, Per Protocol Population ..........................................................105
 
Figure  31: Box Plots of Percentage of Influenza- Specific CD8+ T Cell Subsets 
Expressing Discrete Mem ory Markers (CCR7, CD45RO, CD57) by Study 
Arm and Study Day, Per Protocol Population ..........................................................106  
Figure  32: Box Plots of Percentage of Influenza- Specific CD4+ T Cell Subsets 
Expressing IL -4 or IL -17 by Study Arm and Study Day, Per Protocol 
Population .................................................................................................................106  
Figure  33: Box Plots of Percentage of Influenza- Specific CD4+ T Cell Subsets 
Expressing Blood T Follicular Helper Cells (T FH CD4+CXCR5+PD -1+IL -
21+) by Study Arm and Study Day, Per Protocol Population ..................................106  
Figure  34: Box Plots of Percentage of Influenza- Specific CD4+ T Cell Subsets 
Expressing Blood T Follicular Regulatory Cells (T FR CXCR5+PD -
1+CD25+CD127+) by Study Arm and Study Day, Per Protocol Population ..........106  
Figure  35: Box Plots of Percentage of Influenza- Specific CD4+ T Cell Subsets 
Expressing Blood Tregs (CD25+Foxp3+) by Study Arm and Study Day, Per Protocol Population ..................................................................................................106
 
Figure  36: Maximum Severity of Solicited Systemic Symptoms per Subject by Day 
Post V accination  .......................................................................................................107  
Figure  37: Maximum Severity of Solicited Local Symptoms per Subject by Day Post 
Vaccination  ...............................................................................................................108  
Figure  38: Incidence of Unsolicited Adverse Events by MedDRA¬Æ System Organ Class and Severity  .....................................................................................................109
 
Figure  39: Frequency of Unsolicited Adverse Events by MedDRA System Organ Class 
and Relationship to Study Vaccination .....................................................................110  
Figure  40: Incidence of Unsolicited Adverse Events by MedDRA System Organ Class 
and Relationship to Study Vaccination .....................................................................111  
Figure  41: Laboratory Results by Scheduled Visits: Mean Changes from Baseline by Study Day and Study Arm ‚Äì Chemistry Parameters  ................................................112
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 97 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  42: Laboratory Results by Scheduled Visits: Mean Changes from Baseline by 
Study Day and Study Arm ‚Äì Hematology Parameters  .............................................112  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 98 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  10.1 Disposition of Subjects  
Figure  1: CONSORT Flow Diagram  
 
Allocated to Group 1 (n=x)  
‚ô¶Received allocated intervention (n=x)  
‚ô¶Did not receive allocated intervention (n=x)  
      
Discontinued Intervention (n=x)  
‚ô¶[Reason 1] (x), [Reason 2] (x)  
Early Termination (n=32)  
Analysed for immunogenicity (n= x) 
‚ô¶Excluded from immuno analyses  (n=x) 
[Reason 1] (x), [Reason 2] (x)  
Analy zed for safety (n= x) 
‚ô¶Excluded from safety analyses (n=x)  
Assessed for Eligibility (n= x) 
Excluded* (n= x) 
‚ô¶   [Reason 1] (n=x ) 
   C  f t ti l i k ( ) 
Randomized (n=x ) 
Allocation  
 
Analysis  
 Follow -Up 
 Enrollmen t 
Allocated to Group 1 (n=x)  
‚ô¶Received allocated intervention (n=x)  
‚ô¶Did not receive allocated intervention (n=x)  
      
Allocated to Group 1 (n=x)  
‚ô¶Received allocated intervention (n=x)  
‚ô¶Did not receive allocated intervention (n=x)  
      
Discontinued Intervention (n= x) 
‚ô¶[Reason 1] (x), [Reason 2] (x)  
Early Termination (n=32)  
Discontinued Intervention (n =x) 
‚ô¶[Reason 1] (x), [Reason 2] (x)  
Early Termination (n=32)  
Analysed for immunogenicity (n= x) 
‚ô¶Excluded from immuno analyses  (n=x) 
[Reason 1] (x), [Reason 2] (x)  
Analyzed for safety (n= x) 
‚ô¶Excluded from safety analyses (n=x)  
 
Analysed for immunogenicity (n= x) 
‚ô¶Excluded from immuno analyses (n=x) 
[Reason 1] (x), [Reason 2] (x)  
Analyzed for safety (n= x) 
‚ô¶Excluded from safety analyses (n=x)  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 99 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.2.2 Efficacy /Immunogenicity  Response Figures by Measure, Vaccination, and Study Day 
Figure  2: Box Plots of Percentage of Selected CD4 + T Cell Subsets Expressing Markers After M-
001 Stimulation by Study Arm and Study Day, P er Protocol  Population* 
[Implementation Note: The 5 combinations of markers with the highest GMP should be displayed in separate 
panels of one image file (2 rows, 5 columns). The x-axis should be study day (Baseline, Day 15, Day 36, Day 
43, Day 78, Day 172, Day 186, and Day 200), and the y -axis should be percentage. Do not include an ‚ÄúAll 
Subjects‚Äù panel. ] 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 100 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figures with similar format: 
Figure  3: Box Plots of Percentage of Selected CD4 + T Cell Subsets Expressing Markers After M-
001 Stimul ation by Study Arm and Study Day, Modified Intent -to-Treat Population* 
Figure  4: Box Plots of Percentage of Selected CD8+ T Cell Subsets  Expressing Markers After M-
001 Stimulation by Study Arm and Study Day , Per Protocol Population* 
Figure  5: Box Plots of Percentage of Selected CD8+ T Cell Subsets  Expressing Markers After M-
001 Stimulation by St udy Arm and Study Day, Modified Intent -to-Treat Population* 
Figure  6: Box Plots of Percentage of Selected CD4+ T Cell Subsets  Expressing Markers After 
Seasonal Influenza A Antigen Stimulation by Study Arm and Study Day, P er Protocol  
Population 
Figure  7: Box Plots of Percentage of Selected CD4+ T Cell Subsets  Expressing Markers After 
Pandemic Influenza A Antigen Stimulation by Study Arm and Study Day, P er Protocol 
Population 
Figure  8: Box Plots of Percentage of Selected CD8 + T Cell Subsets  Expressing Markers After 
Seasonal Influenza A Antigen Stimulation by Study Arm and Study Day, P er Protocol  
Population 
Figure  9: Box Plots of Percentage of Selected CD8+ T Cell Subsets  Expressing Markers After 
Pandemic Influenza A Antigen Stimulation by Study Arm and Study Day, P er Protocol 
Population 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 101 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  10: Reverse Cumulative Distribution of  Hemagglutination Inhibition Antibody A gainst 
A/Michigan/45/2015 X-275 (H1N1) by Study Day and Study A rm, Per Protocol  
Population 
[Implementation Note: Plot each time point in a separate panel, with the 2 study arms in different colors 
and/or line types.] 
 Reverse Cumulative Distribution Curves
Hemagglutination Titer
A/New Caledonia/20/99
Pre-Vaccination
IVV without IFN  IVV with 1M IFN
 IVV with 10M IFNCumulative Percent
0102030405060708090100
TITER1.4 4 8 16 32 64 128 256 512 1280 2048 4096Reverse Cumulative Distribution Curves
Hemagglutination Titer
A/New Caledonia/20/99
14 Days Post Vaccination
IVV without IFN  IVV with 1M IFN
 IVV with 10M IFNCumulative Percent
0102030405060708090100
TITER1.4 4 8 16 32 64 128 256 512 1280 2048 4096
Reverse Cumulative Distribution Curves
Hemagglutination Titer
A/New Caledonia/20/99
28 Days Post Vaccination
IVV without IFN  IVV with 1M IFN
 IVV with 10M IFNCumulative Percent
0102030405060708090100
TITER1.4 4 8 16 32 64 128 256 512 1280 2048 4096
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 102 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figures with similar format:  
Figure  11: Reverse Cumulative Distribution of Hemagg lutination Inhibition Antibody A gainst 
A/Singapore/INFIMH -16-0019/2016 NIB-104 (H3N2)- Guinea RBC  by Study Day and 
Study A rm, Per Protocol Population  
Figure  12: Reverse Cumulative Distribution of Hemagg lutination Inhibition Antibody A gainst 
B/Colorado/6/2017 (B Victoria Lineage) by Study Day and Study Arm , Per Protocol  
Population 
Figure  13: Reverse Cumulative Distribution  of Hemagglutination Inhibition Antibody A gainst 
B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day and Study Arm, Per Protocol 
Population 
Figure  14: Reverse Cumulative Distribution of Neutralizing  Antibody A gainst A/Michigan/45/2015 
X-275 (H1N1) by Study Day and Study A rm, Per Protocol  Population 
Figure  15: Reverse Cumula tive Distribution of Neutralizing Antibody A gainst 
A/Singapore/INFIMH -16-0019/2016 NIB-104(H3N2) by Study Day and Study Arm , Per 
Protocol  Population 
Figure  16: Reverse Cumulative Distribution of Neutralizing Antibody  Against B/Colorado/6/2017 (B 
Victoria Lineage) by Study Day and Study Arm , Per Protocol  Population 
Figure  17: Reverse Cumulative Distribution of Neutralizing  Antibody A gainst B/Phuket/3073/2013 
(B Yamagata Lineage) by Study Day and Study A rm, Per Protocol  Population 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 103 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  18: Correlation of Hemagglutination Inhibition Antibody and Neutralizin g Antibody Against A/H1N1 by Study Day and Study A rm, 
Per Protocol  Population 
[Implementation Note: A generic sample figure is shown below. The scatter plots should be presented in a single figure with separate panels for each 
visit. Visit labels should be included in the panel header. Within each panel distinct marker types and colors should be used to indicate the 2 vaccination groups, with vaccination group labels included in a legend. The spearman correlation should be calculated over all subjects and annotated within each 
panel header after the v isit label as ‚Äúr=0.xx, p=0.xx ‚Äù.  The x -axis should be labeled by ‚ÄúHemagglutination Inhibition Antibody (Titer)‚Äù and the y- axis by 
‚ÄúNeutralizing A ntibody (Titer)‚Äù.] 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 104 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figures with similar format: 
Figure  19: Correlation of Hemagglutination Inhibition Antibody and M-001 Antibody Against A/H1N1 by Study Day and Study Arm, Per 
Protocol Population  
Figure  20: Correlation of Neutralizing Antibody and M-001 Antibody Against A/H 1N1 by Study  Day and Study Arm, Per Protocol 
Population 
Figure  21: Correlation of Hemagglutination Inhibition Antibody and Neutralizing  Antibody against A/H3N2 by Study Day and Study A rm, 
Per Protocol  Population 
Figu re 22: Correlation of Hemagglutination Inhibition Antibody and M-001 Antibody Against A/H3N2 by Study Day and Study  Arm, Per 
Protocol Population  
Figure  23: Correlation of Neutralizing Antibody and M-001 Antibody Against A/H3N2 by Study Day and Study Arm, Per Protocol 
Population 
Figure  24: Correlation of Hemagglutination Inhibition Antibody and Neutralizing Antibody A gainst B/Colorado/6/2017 (B Victoria Lineage)  
by Study Day and Study A rm, Per Protocol  Population 
Figure  25: Correlation of Hemagglutinati on Inhibition Antibody and M -001 Antibody Against B/Colorado/6/2017 (B Victoria Lineage) by 
Study Day and Study Arm, Per Protocol Population  
Figure  26: Correlation of Neutralizing Antibody and M-001 Antibody Against B/Colorado/6/2017 (B Victoria Lineage) by Study Day and 
Study Arm, Per Protocol Population 
Figure  27: Correlation of Hemagglutination Inhibition  Antibody and Neutralizing Antibody A gainst B/Phuket/3073/2013 (B Yamagata 
Lineage) by Study Day and Study A rm, Per Protocol  Population 
Figure  28: Correlation of Hemagglutination Inhibition Antibody and M-001 Antibody Against B/Phuket/3073/2013 (B Yamagata Li neage) 
by Study Day and Study  Arm, Per Protocol Population  
Figure  29: Correlation of Neutralizing Antibody and M-001 Antibody Against B/Phuket/3073/2013 (B Yamagata Lineage) by Study Day and 
Study Arm, Per Protocol Population 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 105 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  30: Box Plots of Percentage of Influenza -Specific CD4+ T Cell Subsets Expressing Discrete 
Memory Markers (CCR7, CD45RO, CD57) by Study Arm  and Study Day, P er Protocol 
Population 
[Implementation Note: The x -axis should be study day (Baseline, Day 15, Day 36, Day 43, Day 78, Day 172, 
Day 186, and Day 200), and t he y-axis should be percentage.] 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 106 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figures with similar format: 
Figure  31: Box Plots of Percentage of Influenza- Specific CD8+ T Cell  Subsets Expressing Discrete 
Memory Markers (CCR7, CD45RO, CD57) by Study Arm and Study Day, Per Protocol 
Population 
Figure  32: Box Plots of Percentage of Influenza -Specific CD4+ T Cell Subsets Expressing IL -4 or IL-
17 by Study Arm  and Study Day, P er Protocol  Population 
Figure  33: Box Plots of Percentage of Influenza -Specific CD4+ T Cell Subsets Expressing Blood T 
Follicular Helper Cells (T FH CD4+CXCR5+PD -1+IL-21+) by Study Arm  and Study Day, 
Per Protocol  Population 
Figure  34: Box Plots of Percentage of Influenza -Specific CD4+ T Cell Subsets Expressing Blood T 
Follicular Regulatory Cells (T FR CXCR5+PD-1+CD25+CD127+) by Study Arm  and 
Study D ay, P er Protocol  Population 
Figure  35: Box Plots of Percentage of Influenza -Specific CD4+ T Cell Subsets Expressing Blood 
Tregs (CD25+Foxp3+) by Study Arm  and Study Day, P er Protocol Population 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 107 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.1.1 Solicited A dverse Events  
Figur e 36: Maximum Severity of Solicited Systemic Symptoms per Subject by Day Post Vaccination 
[Implementation Note: The figure can be shaded with the default coloring instead of the patterns.]
 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 108 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figur e 37: Maximum Severity of Solicited Local Symptoms per Subject by Day Post Vaccination 
[Implementation Note: The figure can be shaded with the default coloring instead of the patterns.] 
 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 109 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.1.2 Unsolicited Adverse Events  
Figure  38: Incidence of Unsolicited  Adverse Events by MedDRA ¬Æ System Organ Class and Severity  
[Implementation Note: The SOCs should be sorted in descending inci dence.  The figure can be shaded with the 
default coloring instead of the patterns. ] 
 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 110 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  39: Frequency of Unsolicited Adverse Events by MedDRA System Organ Class and Relationship to Study Vaccination 
[Implementation Note: A Generic figure is shown below. The bar chart should be presented in a single figure with separate panels for each for each 
treatment arm (total 2 panels: 2 rows x 1 column). Axes should be labeled as shown. The treatment arms should be indicated in the panel headers as 
follows: Group 1: 1 mg M -001  (N=X), Group 2: Placebo (N=X), where N = the number of subjects in the in the Safety Population. This figure includes 
serious and non-serious unsolicited adverse events.] 
 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 111 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Figure  40: Incidence of Unso licited Adverse Events by MedDRA System Organ Class and Relationship to Study Vaccination 
[Implementation Note: A Generic figure is shown below. The bar chart should be presented in a single figure with separate panels for each for each 
treatment arm (total 2 panels: 2  rows x 1 column). Axes should be labeled as follows: x-axis: Study Group, y-axis: Number of Events. The treatment 
arms should be indicated in the panel headers as follows: Group 1 : 1 mg M -001 (N=X), Group 2: Placebo  (N=X ) where N = the number of subjects in 
the in the Safety Population. This figure includes serious and non-serious unsolicited adverse events.] 
 
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 112 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  14.3.5 Displays of Laboratory Results 
Figure  41: Laboratory Results by Scheduled Visits: Mea n Changes from Baseline by  Study Day  and Study Arm  ‚Äì Chemistry Parameters  
[Implementation note: Plot should be generated with all s tudy groups in a single image file with panels for each study group (3 row s ‚Äì one for each 
parameter: Alanine Aminotransferas e, Total Bilirubin, Creatinine  for chemistry parameters, White Blood Cells, Hemoglobin, Platelets for hematology 
parameters  ‚Äì by 2 columns ‚Äì one for each group ‚Äì similar  in style to below). Box-plots should be plotted for each post-vaccination visit (Visit 02 & Visit 
05). Y-axis should be labeled ‚Äú[Parameter] Change from baseline ([units]) ‚Äù] 
 
 Figures with similar format: Figure  42: Laboratory Results by Scheduled Visits: Mean Changes from Baseline by Study Day  and Study Arm  ‚Äì Hematology Parameters  
 

Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 113 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  APPENDIX 3. LISTINGS MOCK -UPS  
LISTING  OF LISTING S 
Listing  1: 16.1.6 Listing of Subjects Receiving Investigational Product ..................................115  
Listing  2: 16.2.1 Early Terminations or Discontinued Subjects ...............................................116  
Listing  3: 16.2.2.1 Subject -Specific Protocol Deviations .........................................................117  
Listing  4: 16.2.2.2 Non- Subject -Specific Protocol Deviations .................................................118  
Listing  5: 16.2.3 Subjects Excluded from Analysis Populations ..............................................119  
Listing  6: 16.2.4.1 Demographic Data ......................................................................................120  
Listing  7: 16.2.4.2 Pre-Existing and Concurrent Medical Conditions ......................................121  
Listing  8: 16.2.6.1 Individual Immunogenicity Response Data ‚Äì Hemagglutination 
Inhibition against A/H1N1 .......................................................................................122  
Listing  9: 16.2.6.2 Individual Immunogenicity Response Data ‚Äì Hemagglutination 
Inhibition against A/H3N2 .......................................................................................122  
Listing  10: 16.2.6.3 Individual Immunogenicity Response Data ‚Äì Hemagglutination Inhibition against B/Colorado/6/2017 ......................................................................122
 
Listing  11: 16.2.6.4 Individual Immunogenicity Response Data ‚Äì Hemagglutination 
Inhibition against B/Phuket/3073/2013 ....................................................................122  
Listing  12: 16.2.6.5 Individual Immunogenicity Response Data ‚Äì Neutralizing Antibody 
against A/H1N1  ........................................................................................................122  
Listing  13: 16.2.6.6 Individual Immunogenicity Response Data ‚Äì Neutralizing Antibody against A/H3N2  ........................................................................................................122
 
Listing  14: 16.2.6.7 Individual Immunogenicity Response Da ta ‚Äì Neutralizing Antibody 
against B/Colorado/6/2017 .......................................................................................122  
Listing  15: 16.2.6.8 Individual Immunogenicity Response Data ‚Äì Neutralizing Antibody 
against B/Phuket/3073/2013 .....................................................................................122  
Listing  16: 16.2.6.9 Individual Immunogenicity Response Data ‚Äì ELISA Antibody against M -001 ...........................................................................................................122
 
Listing  17: 16.2.6.10 Individual Immunogenicity Re sponse Data ‚Äì Flow Cytometry 
Results .......................................................................................................................123  
Listing  18: 16.2.6.11 Individual Immunogenicity Response Data ‚Äì Cell Mediated Immunity  ...................................................................................................................124
 
Listing  19: 16.2.7.1 Solicited Events ‚Äì Systemic Symptoms  .....................................................125  
Listing  20: 16.2.7.2 Solicited Events ‚Äì Local Symptoms  ...........................................................126  
Listing  21: 16.2.7.3 Unsolicited Adverse Events ........................................................................127  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 114 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  22: 16.2.8.1 Clinical Laboratory Results ‚Äì Chemistry  ...................................................128  
Listing  23: 16.2.8.2 Clinical Laboratory Results ‚Äì Hematology ................................................129  
Listing  24: 16.2.9.1 Vital Signs ..................................................................................................130  
Listing  25: 16.2.9.2 Physical Exam Findings .............................................................................131  
Listing  26: 16.2.10 Concomitant Medications ............................................................................132  
Listing  27: 16.2.11.1 Pregnancy Reports ‚Äì Maternal Information  .............................................133  
Listing  28: 16.2.11.2 Pregnancy Reports ‚Äì Gravida and Para  ....................................................133  
Listing  29: 16.2.11.3 Pregnancy Reports ‚Äì Live Birth Outcomes ..............................................134  
Listing  30: 16.2.11.4 Pregnancy Reports ‚Äì Still Birth Outcomes  ...............................................134  
Listing  31: 16.2.11.5 Pregnancy Reports ‚Äì Spontaneous, Elective, or Therapeutic 
Abortion Outcomes ...................................................................................................134  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 115 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.1.6 Listing of Subjects Receiving Investigational Product 
Listing  1: 16.1.6 Listing of Subjects Receiving Investigational Product 
Randomized Treatment Group  Actual Treatment Group   Subject ID  Enrollment Date  
    
    
    
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 116 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2 Database Listings by Subject 
16.2.1 Discontinued Subjects  
Listing  2: 16.2.1 Early Terminations or Discontinued Subjects  
[Implementation Note: In the ‚ÄúReason‚Äù column, concatenate any ‚Äúspecify‚Äù fields, including AE number and DV number. In the CSR, Subject ID should 
be USUBJID (not PATID). Listings should be sorted by Study Arm, then by Subject ID, and here then alphabetically by Category.] 
Study Arm   Subject ID  Category  Reason for Early Termination or Treatment Discontinuation  Study Day  
     
     
     
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 117 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.2 Protocol Deviations 
Listing  3: 16.2.2.1 Subject -Specific Protocol Deviations  
Study Arm  Subject ID  DV Number  Deviation  Deviation 
Category  Study Day  Reason for  
Deviation  Deviation 
Resulted  
in AE?  Deviation Resulted 
in Subject 
Termination?  Deviation  
Affected Product  
Stability?  Deviation 
Resolution  Comments  
            
            
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 118 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  4: 16.2.2.2 No n-Subject -Specific Protocol Deviations  
Site Start Date  Deviation  End Date  Reason for  
Deviation  Deviation Resulted in 
Subject Termination?  Deviation  Affected  
Product  Stability?  Deviation  
Category  Deviation 
Resolution  Comments  
          
          
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 119 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.3 Subjects Excluded from the Efficacy Analysis 
Listing  5: 16.2.3 Subjects Excluded from Analysis Populations  
Study Arm  Subject ID  Analyses in which 
Subject is Included  Analyses from which  
Subject is Excluded  Results Available?  Reason Subject Excluded  
  [e.g., Safety, mITT, PP]  [e.g., Safety, mITT, PP, Day x]    
      
      
      
      
Note: ‚ÄúYes‚Äù in the ‚ÄúResults available‚Äù column indicates that available data were removed from the analysis. ‚ÄúNo‚Äù indicates th at no data were av ailable for inclusion in the analysis.  
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 120 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.4 Demographic Data 
Listing  6: 16.2.4.1 Demographic Data  
Study Arm  Subject ID  Sex Age at Enrollment (years)  Ethnicity Race  Prior Seasonal Influenza Vaccination  
       
       
       
       
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 121 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  7: 16.2.4.2 Pre- Existing  and Concurrent  Medical Conditions  
Study Arm  Subject ID  MH Number  Medical History Term  Condition Start Day  Condition End Day  MedDRA System Organ Class  MedDRA Preferred Term  
        
        
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 122 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.6 Individual Immunogenicity  Response Data  
Listing  8: 16.2.6.1 Individual Immunogenicity Response Data  ‚Äì Hemagglutination Inhibition against A/H1N1 
Study Arm   Subject ID   Planned Study Day  Actual Study Day  Titer 
     
     
     
     
     
     
     
     
 
Listings with similar format: 
Listing  9: 16.2.6.2 Individual Immunogenicity Response Data ‚Äì Hemagglutination Inhibition against A/H3N2  
Listing  10: 16.2.6.3 I ndividual Immunogenicity Response Data ‚Äì Hemagglutination Inhibition against B/Colorado/6/2017 
Listing  11: 16.2.6.4 Individual Immunogenicity Response Data ‚Äì Hemagglutination Inhibition against B/Phuket/3073/2013 
Listing  12: 16.2.6.5 Individual Immunogenicity Response Data ‚Äì Neutralizing Antibody against A/H1N1 
Listing  13: 16.2.6.6 Individual Immunogenicity Response Data ‚Äì Neutralizing Antibody against A/H3N2 
Listing  14: 16.2.6.7 Individual Immunogenicity Response Data ‚Äì Neutralizing Antibody against B/Colorado/6/2017 
Listing  15: 16.2.6.8 Individual Immunogenicity Response Data ‚Äì Neutralizing Antibody against B/Phuket/3073/2013 
Listing  16: 16.2.6.9 Individual Immunogenicity Response Data ‚Äì ELISA Antibody against M-001 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 123 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  17: 16.2.6.10 Individual Immunogenicity Response Data ‚Äì Flow Cytometry Results 
Study Arm  Subject ID   Planned Study Day  Actual Study Day  % Influenza -Specific T Cell 
Memory Subsets Expressing 
Discrete Memory Markers  % CD4 T Cells 
Expressing IL -4 or 
IL-17 % CD4 T Cells 
Expressing Tfh 
Cells  % CD 4 T Cells 
Expressing Tfr 
Cells  % CD4 T Cells 
Expressing Tregs  
         
         
         
         
         
         
         
         
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 124 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  18: 16.2.6.11 Individual Immunogenicity Response Data ‚Äì Cell Mediated Immunity  
Study Arm  Subject ID   Planned Study Day  Actual Study Day  Stimul us (M -001 
Peptides or Influenza 
A Antigens)  Cell Type (CD4 or 
CD8)  Cytokine 
Combination  Percentage T Cells 
Expressing 
Combination  
        
        
        
        
        
        
        
        
Note s: Cytokines are perforin, CD107a, IFN -Œ≥, TNF -Œ±, and IL2.   
Do not include rows where the percentage expressed is 0.  
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 125 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.7 Adverse Events  
Listing  19: 16.2.7.1 Solicited Events  ‚Äì Systemic  Symptoms  
Study Arm   Subject ID   Dose Numbe r Post Dose Day  Assessmenta Symptom  Severity  Attributed to 
Alternate 
Etiology?b Alternate Etiology  
    MA     
    Clinic      
         
         
Note s: Clinic = Data collected by clinic staff during physical exam or symptom assessment ( treatment adminis tration record, in -clinic assessment,  etc.) 
a MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.  
b Grade 3 events only.   
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 126 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  20: 16.2.7.2 Solicited Events ‚Äì Local Symptoms 
Study Arm   Subject ID   Dose Number  Post Dose Day  Assessmenta Symptom  Severity  
    MA   
    Clinic    
       
       
Note s: Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record,  in-clinic assessment, etc.)  
a MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.  
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 127 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  21: 16.2.7.3 Unsolicited Adverse Events  
Adverse 
Event  Associated 
with Dose 
No. No. of Days 
Post 
Associated 
Dose 
(Duration)  Severity  SAE?  Relationship 
to Study 
Treatment  In Not 
Related, 
Alternative 
Etiology  Action 
Taken with 
Study 
Treatment  Subject 
Discontinued 
Due to AE  Outcome  MedDRA 
System 
Organ Class  MedDR A 
Preferred 
Term  
Study Arm : , Subject ID: , AE Number:   
            
Comments:  
            
Study Arm : , Subject ID: , AE  Number:   
            
Comments:  
Note: For additional details about SAEs, see Table: xx.  
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 128 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.8 Individual Laboratory Measurem ents 
Listing  22: 16.2.8.1 Clinical Laboratory Results ‚Äì Chemistry  
Study Arm  Subject ID  Planned 
Study Day   Actual 
Study Day  Sex  Age (years)  Laboratory Parameter 
(Units)  Result (Severity 
Grade)  Reference Range 
Low  Reference Range 
High  
          
          
          
          
          
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 129 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  23: 16.2.8.2 Clinical Laboratory Results ‚Äì Hematology 
Study Arm  Subject ID  Planned Study 
Day  Actual 
Study 
Day  Sex  Age 
(years)  Laboratory Parameter 
(Units)  Result (Severity 
Grade)  Reference Range 
Low  Reference Range 
High  
          
          
          
          
          
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 130 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.9 Vital Signs and Physical Exam Findings  
Listing  24: 16.2.9.1 Vital Signs  
Study Arm  Subject ID  Planned 
Study Day  Actual Study 
Day Temperature  
(¬∞C) Systolic Blood 
Pressure  
(mmHg)  Diastolic Blood 
Pressure  
(mmHg)  Heart Rate  
(beats/min)  Respiratory Rate  
(breaths/min)  Weight  
(kg) Height  
(cm)  
           
           
           
           
           
 
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 131 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  25: 16.2.9.2 Physical Exam Findings 
Study Arm  Subject ID  Planned Study 
Day Actual Study 
Day Body System  Abnormal Finding  Reported as an AE?  
(AE Description; Number)  
       
       
       
       
       
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 132 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.10 Concomitant M edications  
Listing  26: 16.2.10 Concomitant Medications 
Study Arm  Subject ID  CM 
Number  Medication  Medication Start 
Day Medication End 
Day Indication  Taken for an AE?  
(AE Description; 
Number)  Taken for a condition 
on Medical History ? 
(MH Description; 
Number)  ATC Level 1  
(ATC Level 2) 
          
          
          
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 133 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  16.2.11 Pregnancy Reports  
Listing  27: 16.2.11.1 Pregnancy Reports  ‚Äì Maternal Information 
Study 
Arm   Subject 
ID  Pregnancy 
Number  Study Day 
Corresponding 
to Estimated 
Date of 
Conception  Source of 
Maternal 
Information  Pregnancy 
Status Mother‚Äôs 
Pre-
Pregnancy 
BMI Mother‚Äôs 
Weight 
Gain 
During 
Pregnancy  Tobacco, 
Alcohol, or 
Drug Use 
During 
Pregnancy?  Medications 
During 
Pregnancy?  Maternal 
Complication s 
During 
Pregnancy?  Maternal 
Complications 
During Labor, 
Delivery, or 
Post-Partum?  
            
            
Note s: Maternal Complications are included in the Adverse Event listing.  
Medications taken during pregnancy are included in the Concomitant Medica tions Listing.  
 
Listing  28: 16.2.11.2 Pregnancy Reports ‚Äì Gravida and Para 
   Live Births       
Subject 
ID Pregnancy 
Number  Gravida  Extremely 
PBa Very 
Early 
PBa Early 
PBa Late 
PBa Early 
TBa Full 
TBb Late 
TBb Post 
TBb Still 
Births  Spontaneous 
Abortion/ 
Miscarriage Elective 
Abortions  Therapeutic 
Abortions  Major 
Congenital 
Anomaly 
with Previous 
Pregnancy?  
                
                
Note s: Gravida includes the current pregnancy, para events do not.  
a Preterm Birth  
b Term Birth  
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 134 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  Listing  29: 16.2.11.3 Pregnancy Reports ‚Äì Live Birth Outcomes  
Subject  
ID Pregnancy 
Number  Fetus 
Number  Pregnancy 
Outcome (for 
this Fetus)  Fetal Distress 
During Labor 
and Delivery?  Delivery 
Method  Gestational 
Age at Live 
Birth  Size for 
Gestational 
Age Apgar 
Score, 1 
minute  Apgar 
Score, 5 minutes  Cord 
pH Congenital 
Anomalies?  Illnesses/ 
Hospitalizations 
within 1 Month of 
Birth?  
             
             
Note: Congenital Anomalies are included in the Adverse Event listing.  
 
Listing  30: 16.2.11.4 Pregnancy Reports ‚Äì Still Birth Outcomes  
Subject  
ID Date of 
Initial 
Report  Fetus 
Number  Pregnancy 
Outcome 
(for this 
Fetus)  Fetal Distress 
During 
Labor and 
Delivery?  Delivery 
Method  Gestational 
Age at Still 
Birth Size for 
Gestational 
Age Cord pH  Congenital 
Anomalies?  Autopsy 
Performed?  If Autopsy, Etiology 
for Still Birth 
Identified?  
            
 
Listing  31: 16.2.11.5 Pregnancy Reports ‚Äì Spontaneous, Elective, or Therapeutic Abortion O utcomes  
Subject  
ID Date of Initial 
Report  Fetus Number  Pregnancy Outcome 
(for this Fetus)  Gestational Age at 
Termination Abnormality in Product of Conception?  Reason for Therapeutic 
Abortion  
       
 
Statistical Analysis Plan - DMID P rotocol: 14-0112  Version 1.0 
09September2019 
- 135 - 
PRIVILEGED AND CONFIDENTIAL COMMUNICATION  APPENDIX 4. NCA TEMPLATE  
See separate document, if applicable. 